Search

Your search keyword '"C. Camps"' showing total 470 results
Start Over Author "C. Camps"

Refine your results

470 results on '"C. Camps"'

51. 70-gene signature, an encouraging prognostic tool to guide adjuvant therapy in early breast cancer

Author

C. Camps Herrero, M.C. Godes Sanz de Bremond, I. Shaheen, M. Gil Raga, Vincenzo Sforza, C. Caballero Diaz, A.J. Cunquero Tomas, A. Blasco Cordellat, Armas Pérez, Alfonso Berrocal, M.J. Safont Aguilera, V. Iranzo Gonzalez-Cruz, L.D. Condori Farfan, M. Meri Abad, A. Rodriguez Huaman, F.D.A. Aparisi Aparisi, C. Avila Andrade, and A.B. Fernandez Diaz

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, 030206 dentistry, Hematology, Gene signature, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, Adjuvant therapy, Medicine, business, Early breast cancer
Published
2017

52. Cutaneous Toxicity Associated With Cetuximab Treatment in Metastatic Colorectal Cancer

Author

S. Villanueva-Herraiz, M.P. Ortega-García, M.A. López-Montenegro Soria, A. Pérez-Feliu, C. Camps-Herrero, and E. Rodríguez-Murphy

Subjects
medicine.medical_specialty, Cetuximab, Colorectal cancer, business.industry, Cancer, Retrospective cohort study, medicine.disease, Dermatology, Acneiform eruption, Surgery, Toxicity, medicine, Medical history, medicine.symptom, Adverse effect, business, medicine.drug
Abstract

Objective: To evaluate the impact and type of side-effects in patients treated with cetuximab and provide a description of the general measures and treatment. Methods: Retrospective safety study. We included all patients that received cetuximab from January to December 2009. All information was obtained from the Pharmacy and Oncology Department’s Access databases and reviewed the patient’s medical history. All data was registered in an Excel workbook. Skin toxicity was graded by the current National Cancer Institute-Common Toxicity Criteria (NCI-CTC). Results: During the study period 43 patients received treatment with cetuximab. Acneiform eruption was present in 30 of the cases (69.8%): 14 patients with grade 1 (48.3%), 13 with grade 2 (44.8%) and 3 with grade 3 (10.3%). These adverse effects appeared in a median of seven (4---28) days. In a median of 40 (20---56) days, ten patients (23.3%) presented xerosis, and three (7%) suffered painful fissures in hands and feet after a median of 28 (21---35) days. Paronychia was present in two patients after a median of 42 (35---49) days. Finally, an alteration in hair growth was observed in two patients with overgrowth of facial hair and one patient with overgrowth of the eyelashes. Five patients presented important conjunctivitis. Three infusion reactions occurred.

Published
2011

53. Toxicidad cutánea asociada a cetuximab en cáncer colorrectal metastásico

Author

S. Villanueva-Herraiz, A. Pérez-Feliu, M.P. Ortega-García, M.A. López-Montenegro Soria, C. Camps-Herrero, and E. Rodríguez-Murphy

Subjects
Pharmacology, medicine.medical_specialty, Cetuximab, business.industry, Cancer, Pharmacy, medicine.disease, Dermatology, Acneiform eruption, Surgery, Paronychia, medicine, Medical history, medicine.symptom, business, Adverse effect, medicine.drug, Patient education
Abstract

OBJECTIVE: To evaluate the impact and type of side-effects in patients treated with cetuximab and provide a description of the general measures and treatment. METHODS: Retrospective safety study. We included all patients that received cetuximab from January to December 2009. All information was obtained from the Pharmacy and Oncology Department's Access databases and reviewed the patient's medical history. All data was registered in an Excel workbook. Skin toxicity was graded by the current National Cancer Institute-Common Toxicity Criteria (NCI-CTC). RESULTS: During the study period 43 patients received treatment with cetuximab. Acneiform eruption was present in 30 of the cases (69.8%): 14 patients with grade 1 (48.3%), 13 with grade 2 (44.8%) and 3 with grade 3 (10.3%). These adverse effects appeared in a median of seven (4-28) days. In a median of 40 (20-56) days, ten patients (23.3%) presented xerosis, and three (7%) suffered painful fissures in hands and feet after a median of 28 (21-35) days. Paronychia was present in two patients after a median of 42 (35-49) days. Finally, an alteration in hair growth was observed in two patients with overgrowth of facial hair and one patient with overgrowth of the eyelashes. Five patients presented important conjunctivitis. Three infusion reactions occurred. A grade-based treatment algorithm was used for all patients that presented cutaneous toxicity. CONCLUSIONS: A considerable number of patients treated with cetuximab develop dermatological side-effects which left untreated could represent a threat to the efficacy of the therapy. Therefore effective management is mandatory, patient education and immediate treatment based on a grade-based algorithm to alleviate symptoms is necessary, so that patient compliance is guaranteed.

Published
2011

54. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

Author

M. Constenla Figueiras, J. Salvador Bofill, Margarita Feyjoo, E. Aranda Aguilar, J.J. Cruz Hernandez, A. Carrato Mena, Pere Gascón, Begoña Soler, C. Camps, J. Garcia Foncillas, A. Anton Torres, E. Diaz Rubio, Y. Escobar, V. Guillem Porta, and R. Lopez Lopez

Subjects
Clinical Practice, medicine.medical_specialty, Constipation, Oncology, business.industry, medicine, Hematology, medicine.symptom, Intensive care medicine, business
Published
2018

55. The quality oncology practice initiative program: Experience in Spain

Author

Álvaro Rogado, J.J. Cruz Hernandez, E. Aranda Aguilar, C. Camps, E. Diaz Rubio, A. Anton Torres, Margarita Feyjoo, Pere Gascón, V. Guillem Porta, R. Lopez Lopez, J. Garcia Foncillas, I.S. Lugo Cuan, M. Constenla Figueiras, and A. Carrato Mena

Subjects
Oncology, Nursing, business.industry, media_common.quotation_subject, Medicine, Quality (business), Hematology, business, media_common
Published
2018

56. Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study

Author

A. Carrato Mena, V. Guillem Porta, Diana Monge, R. Lopez Lopez, Fernando Caballero, J. Garcia Foncillas, Margarita Feyjoo, E. Aranda Aguilar, J. J. Reina Zoilo, E. Diaz Rubio, and C. Camps

Subjects
Audit study, medicine.medical_specialty, Oncology, business.industry, Physical therapy, Medicine, Hematology, business, Cancer pain
Published
2018

57. Estudio de utilización de pemetrexed en el cáncer de pulmón no microcítico

Author

C. Camps-Herrero, M.P. Ortega-García, P. Blasco-Segura, and S. Villanueva-Herraiz

Subjects
Pharmacology, medicine.medical_specialty, Chemotherapy, Taxane, business.industry, medicine.medical_treatment, Retrospective cohort study, Disease, medicine.disease, Surgery, Pemetrexed, Internal medicine, Medicine, Adenocarcinoma, Stage (cooking), business, Adverse effect, medicine.drug
Abstract

Objective: To study the effectiveness and safety of pemetrexed in non-small cell lung cancer. Method: Retrospective study (March 2006-May 2008) of pemetrexed use. Information was obtained from the Access database belonging to the Pharmacy and Oncology Departments, the registry of external consultations and clinical histories. Data were analysed using SPSS software version 12.0. Quantitative variables are expressed as the median (minimummaximum). Results: The study included 44 patients (61.7 [39-77] years old), mostly male (86%), smokers or former smokers (80%) with predominantly epidermoid/squamous disease (46%) or adenocarcinoma, in a good functional state (86%) and in stage >III upon beginning pemetrexed treatment (93%). Prior treatment with taxanes and taxane treatment along with a prior history of neutropoenia were the criteria for changing to pemetrexed in 34.4% and 22.7% of the patients, respectively. None of the patients presented a complete or partial response: 18.2% showed disease stability and 81.8% showed disease progression. The main reasons for discontinuing pemetrexed were progression of the disease (54.5%) and worsening of symptoms (15.9%). Median survival after beginning chemotherapy was 22.2 months (ranging from 16-28.4) and 7.8 months (4.4-11.2) after beginning pemetrexed treatment. These last figures were significantly higher in women and those with an ECOG of 0 to 1. The most common adverse effects were weakness and neurotoxicity. Conclusion: In each of the cases, pemetrexed was used as a second-line treatment or higher with a good safety profile. A complete or partial response was not reached in any of the cases, but survival after beginning pemetrexed was equal to or longer than that achieved in other studies.

Published
2010

58. Farmacoeconomía y los costes de los medicamentos contra el cáncer

Author

C. Caballero Diaz, A. Blasco Cordellat, and C. Camps Herrero

Subjects
Pharmacology, Gerontology, Consumption (economics), Actuarial science, Cost–benefit analysis, business.industry, Cost effectiveness, MEDLINE, Disease, Pharmacoeconomics, Medicine, Economic impact analysis, High incidence, business
Abstract

Cancer is a disease of high incidence, which determines that the health systems will be forced to allocation a significant amount of resources. In an era of evidence-based medicine and increasing cost pressures, it is important to understand the relative clinical and economic impact of the many drug treatment strategies available for cancer patients. Currently, resources that may be spent in pharmacoeconomics expenditure are limited so it is necessary to rationalize their consumption and priorize in the allocation of these resources to the options with higher economic advantages. Pharmacoeconomic studies will permit us to know what is the efficiency of different therapeutic alternatives so they will help to determine the therapeutic options that we should use in routine medical practice.

Published
2010

60. Study of use of pemetrexed in non-small cell lung cancer

Author

C. Camps-Herrero, P. Blasco-Segura, S. Villanueva-Herraiz, and M.P. Ortega-García

Subjects
medicine.medical_specialty, Chemotherapy, Taxane, business.industry, medicine.medical_treatment, Retrospective cohort study, medicine.disease, Surgery, Pemetrexed, Internal medicine, medicine, Adenocarcinoma, Stage (cooking), business, Adverse effect, Lung cancer, medicine.drug
Abstract

Objective To study the effectiveness and safety of pemetrexed in non-small cell lung cancer. Method Retrospective study (March 2006-May 2008) of pemetrexed use. Information was obtained from the Access database belonging to the Pharmacy and Oncology Departments, the registry of external consultations and clinical histories. Data were analysed using SPSS software version 12.0. Quantitative variables are expressed as the median (minimum-maximum). Results The study included 44 patients (61.7 [39–77] years old), mostly male (86%), smokers or former smokers (80%) with predominantly epidermoid/squamous disease (46%) or adenocarcinoma, in a good functional state (86%) and in stage ≥III upon beginning pemetrexed treatment (93%). Prior treatment with taxanes and taxane treatment along with a prior history of neutropoenia were the criteria for changing to pemetrexed in 34.4% and 22.7% of the patients, respectively. None of the patients presented a complete or partial response: 18.2% showed disease stability and 81.8% showed disease progression. The main reasons for discontinuing pemetrexed were progression of the disease (54.5%) and worsening of symptoms (15.9%). Median survival after beginning chemotherapy was 22.2 months (ranging from 16–28.4) and 7.8 months (4.4–11.2) after beginning pemetrexed treatment. These last figures were significantly higher in women and those with an ECOG of 0 to 1. The most common adverse effects were weakness and neurotoxicity. Conclusion In each of the cases, pemetrexed was used as a second-line treatment or higher with a good safety profile. A complete or partial response was not reached in any of the cases, but survival after beginning pemetrexed was equal to or longer than that achieved in other studies.

Published
2010

61. L’implant Tie-in peut-il être utilisé dans les reprises de rhizarthrose ? Courbe de survie sur 10 ans

Author

Damien Cheval, Thomas Jager, Michel Merle, Bernard Lallemand, and C. Camps

Subjects
Rehabilitation, Orthopedics and Sports Medicine, Surgery
Abstract

Les echecs apres chirurgie de la rhizarthrose sont rares, mais difficiles a prendre en charge, du fait du collapsus de la loge trapezienne et de l’atteinte des parties molles. L’implant Tie-in en silicone permet de redonner facilement la hauteur. Contrairement a la prothese de Swanson, le dessin particulier de l’implant Tie-in doit limiter l’instabilite grâce a une ligamentoplastie associee. L’utilisation de cet implant peut donc etre interessante pour corriger le collapsus dans les reprises, tout en evitant une usure rapide grâce a la stabilisation ligamentaire. Pour confirmer cette hypothese, nous avons cherche a connaitre la survie de cet implant dans les reprises de rhizarthrose. Patients et methode Il s’agit d’une etude retrospective unicentrique. Entre janvier 2005 et decembre 2015, 22 implants ont ete poses pour la reprise de rhizarthrose (trapezectomie, prothese, implant d’interposition Arex ou ligamentoplastie). Le sex-ratio etait de 17 femmes pour 5 hommes. L’âge moyen a la pose etait de 57 ans (40–72 ans). Tous les dossiers ont ete revus par un observateur independant. Nous avons recherche la date de pose de l’implant et la date de diagnostic de l’echec (rupture, usure importante, luxation, ou mauvaise tolerance clinique). Nous avons realise une courbe de survie selon la methode de Kaplan et Meyer. Resultats La mediane de survie est de 2,15 ans. A 4 ans, il ne restait que 30 % d’implants sans problemes. Seul 3 patients n’ont pas presente d’usure, mais l’un des trois n’a pas ete revu a plus d’un an de recul. Nous avons retrouve 47 % de rupture, 32 % de luxation, 16 % d’usure et 5 % de douleur residuelle. Quarante-deux pour cent des echecs presentaient une siliconite. La survie de l’implant Tie-in, dans les reprises, est mauvaise avec pres de la moitie des implants presentant une cause d’echec a 2 ans. Le taux de siliconite est egalement important et necessite une reprise chirurgicale difficile du a des lesions osseuses. Dans ces reprises, la ligamentoplastie et la suture capsulaire sont souvent de mauvaise qualite. La stabilite de la prothese est donc insuffisante, expliquant ainsi ces usures et luxations. De plus, le dessin de l’implant, pour permettre a une stabilisation, augmente la fragilite et le risque de rupture. Dans les reprises des echecs de rhizarthrose, l’implant Tie-in ne doit plus etre utilise.

Published
2017

62. La douleur est-elle un facteur de risque de survenue d’un SDRC après fracture du radius distal ?

Author

A. Durand, Thomas Jager, C. Camps, Andréa Falcone, Christophe Duysens, and Michel Merle

Subjects
Rehabilitation, Orthopedics and Sports Medicine, Surgery
Abstract

Une etude evaluant de facon prospective les patients operes d’une fracture du poignet par plaque palmaire est menee dans notre service depuis 2008. L’objectif est d’evaluer les resultats fonctionnels et radiographiques de l’osteosynthese par plaque palmaire verrouillee et du protocole d’auto-reeducation precoce. Nous avons recherche les facteurs de risque de survenue d’un syndrome douloureux regional complexe (SDRC). Notre serie comportait 122 fractures du radius distal chez 118 patients. Le ratio homme femme etait de 20,98. L’âge moyen etait de 66 ans (17–91 ans). Soixante-quatorze patients etaient retraites (62,71 %). Nous avons analyse le type d’anesthesie, la duree de sejour, le delai accident-intervention, la necessite d’une arthroscopie, l’ablation du materiel. Le debut et la duree du protocole d’auto-reeducation ont ete notes. Chaque patient a ete revu au 21e, 45e, 90e, 180e et 365e jour, avec evaluation des douleurs (EVA), mesure des amplitudes du poignet, evaluation de la souplesse digitale, du score de Kapandji, de la force au dynamometre de Jamar. A un an de recul, le QuickDash etait calcule. La survenue de complication a ete relevee. Les radiographies ont ete analysees, et les fractures classees selon l’AO resultats. La recherche d’une correlation entre les parametres cliniques, radiographiques et fonctionnels a ete menee en comparant les patients atteints d’un SDRC et les autres. Quatre patients ont presente un SDRC, soit 3,28 %. Il n’y a pas, dans cette etude, de correlation entre le sexe et la survenue d’un SDRC (p = 0,6779), ni avec le type de fracture A, B ou C (p > 0,05). Les deux parametres significativement associes a la survenue d’un SDRC sont la douleur (EVA ≥ 5) a la 3e semaine (p = 1,14E−5) et le QuickDash a un an (p = 0,0003). Discussion Aucun demontage de l’osteosynthese n’a ete constate, deplacement dans 97,55 % des cas. Plus de 70 % de la mobilite finale etaient obtenus a la 6e semaine. La douleur precoce est un facteur de risque de survenue d’un SDRC. Nos resultats confirment les conclusions de Moseley sur le « signal d’alerte » de la douleur sur l’EVA, justifiant un traitement preventif un suivi rapproche. Cette etude confirme l’efficacite de l’osteosynthese par plaque palmaire verrouillee pour les fractures du radius distal, meme chez les patients âges.

Published
2017

63. [Treatment of partial articular fractures of the distal radius in active young adults]

Author

C, Camps, A, Durand, and M, Merle

Subjects
Adult, Wrist Joint, Arthroscopy, Fracture Fixation, Internal, Young Adult, Treatment Outcome, Humans, Radius Fractures
Abstract

The wrist's function is at stake in young active adults with partial intra-articular fractures of the distal radius. The high energy nature of these injuries, displaced fractures with risk of malunion in case of insufficient treatment, and associated ligament or cartilage damage all hinder the prognosis of these fractures. Many classification systems exist to help us analyze and in some cases, select a treatment. Optimal management requires a high-quality preoperative assessment and a precise surgical technique coupled with the use of arthroscopy to deal with joint and ligament injuries in the same operation. Devices that address the fragmented nature of these fractures provide the best fixation. The primary treatment goal is reduction with less 1mm intra-articular step-off in order to reduce the risk of secondary osteoarthritis and to treat associated ligament damage, which is very common and often under-estimated. Treating the fracture and any associated lesions during the same operation is the best way to ensure a good functional outcome.

Published
2015

64. [Treatment of intra-articular malunion of the distal radius of young active patients]

Author

A, Durand, C, Camps, and M, Merle

Subjects
Adult, Arthroscopy, Fracture Fixation, Internal, Postoperative Complications, Treatment Outcome, Intra-Articular Fractures, Age Factors, Humans, Radius Fractures, Tomography, X-Ray Computed, Wrist Injuries, Fractures, Malunited
Abstract

Management of malunion of the distal radius remains difficult. Planning of the correction of the articular displacement requires a comprehensive analysis by CT arthrography to analyze bone, cartilage and ligaments. Arthroscopy is a valuable tool in the context of joint trauma. In the absence of osteoarthritis, the correction can be carried out as early as possible in the weeks or months following the initial fracture. The use of locking plates allows early mobilization after surgery. This correction aims to prevent the development of secondary osteoarthritis.

Published
2015

66. Time resolution of a photomultiplier readout system for space application

Author

H. von Gunten, A. Lebedev, C. Camps, S.C. Commichau, V. Commichau, M. Capell, J. Mnich, K. Hangarter, Ulf Roser, G. Viertel, and Günter Flügge

Subjects
Physics, Nuclear and High Energy Physics, Photomultiplier, Photon, Large Hadron Collider, Physics::Instrumentation and Detectors, business.industry, Detector, Synchrotron radiation, Scintillator, Particle detector, Optics, Nuclear magnetic resonance, Alpha Magnetic Spectrometer, High Energy Physics::Experiment, business, Instrumentation
Abstract

The performance of a readout system for the Synchrotron Radiation Detector (SRD) is studied. The detector is proposed as part of the Alpha Magnetic Spectrometer experiment, an experiment to fly on the International Space Station (ISS) beginning of 2005. The SRD is designed to detect the synchrotron radiation from electrons and positrons (TeV energy range) produced in the earth's magnetic field. For the planned array of scintillators and photomultipliers a readout system is chosen, which is compact, space qualified and has a low-power consumption. The low-power chip APV, originally designed for the CMS experiment at LHC (CERN), is foreseen for the readout. To overcome the diffuse background from photons and charged particles the SRD readout must have a time resolution better than 10 ns. The intrinsic time resolution (sigma from Gauss fit) of the APV25-S0 was found to be 0.46±0.01 and 0.68±0.02 ns for the APVM, whereas the time resolution of the photomultiplier-APV readout system was measured to be 2.73±0.10 ns for the APV25-S0 and 2.90±0.21 ns for the APVM. The investigated timing capabilities of the photomultiplier-APV readout system show that the APV chip is suitable for the SRD readout.

Published
2004

67. Évolution nutritionnelle au cours de la première année de vie des enfants dépistés pour la mucoviscidose

Author

Emmanuel Mas, C. Camps-Guiran, Sylvain Blanchon, M. Mittaine, M. Nau, F. Brémont, and G. Labouret

Subjects
Pediatrics, Perinatology and Child Health
Abstract

But Evaluer l’impact du depistage neonatal de la mucoviscidose sur l’evolution nutritionnelle precoce. Methode Etude retrospective monocentrique realisee du 1/10/02 au 31/12/12 qui a evalue au moment du diagnostic et vers un an les parametres nutritionnels cliniques et biologiques. L’analyse a ete faite en 3 sous-groupes en fonction de la valeur de l’elastase fecale initiale : suffisant (SP), intermediaire et insuffisant pancreatique (IP), respectivement elastase > 200, 15–200 et t de Student non apparie pour les variables continues, exprimees en moyenne ± DS, et en un test de Chi 2 pour les variables categorielles, exprimees en pourcentage. Resultats Cinquante-deux enfants ont ete diagnostiques durant cette periode dont 43 par depistage neonatal (7 pathologies chirurgicales neonatales et 2 faux negatifs). Ils etaient repartis en 8 SP (17 %), 10 intermediaires (21 %) et 28 IP (59 %). Lors de l’annonce, a 37 ± 14 jours, le poids etait significativement plus bas dans le groupe IP (−1,13 ± 1,18 DS, p p Au niveau biologique, les valeurs au diagnostic de l’albumine et du zinc serique etaient plus basses dans le groupe IP. Au cours du suivi, a ete notee une augmentation des taux d’acide eicosapentaenoique et une diminution du taux d’acide docosahexaenoique quel que soit le statut pancreatique. Concernant les vitamines liposolubles, la principale difference concernait la vitamine E dont le taux etait significativement plus bas au diagnostic dans le groupe IP vs. SP, respectivement de 5,8 ± 4,2 vs. 11,1 ± 3,4 mg/L ( p = 0,01). Conclusion Le depistage neonatal de la mucoviscidose a permis une correction a un an des anomalies nutritionnelles presentes au moment du diagnostic. Toutefois, une attention particuliere doit etre portee aux nourrissons ayant une fonction pancreatique « intermediaire », dont le statut nutritionnel a un an etait moins bon.

Published
2016

68. Experience with the L3 vertex drift chamber at LEP

Author

H. Anderhub, André Holzner, V. Commichau, R. Leiste, Christoph Paus, P. Schmitz, C. Camps, Wolfgang Lohmann, H. Vogt, Christoph Schäfer, P. Wienemann, H. Hofer, A.S. Schmidt-Kärst, H. Szczesny, Max Weber, H. von Gunten, P. Göttlicher, L. Djambazov, M. Sassowsky, F. Beissel, Ulf Roser, K. Hangarter, Werner Lustermann, B. L. Betev, S. Waldmeier, Martin Pohl, A. Straessner, T. Spickermann, G. Viertel, A. Böhm, J. Mnich, U. Horisberger, G. Rahal, Adrian Biland, Dimitri Bourilkov, H. Suter, and Andreas Kopp

Subjects
Physics, Nuclear and High Energy Physics, Physics::Instrumentation and Detectors, ddc:500.2, Radiation, Charged particle, Particle detector, Vertex (geometry), Anode, Nuclear physics, Pulse-amplitude modulation, Electrode, Measuring instrument, High Energy Physics::Experiment, Instrumentation
Abstract

The vertex drift chamber of the L3 Experiment at LEP, based on the time expansion principle, was in operation from the start-up of LEP in 1989 until the shutdown of LEP in 2000. The gas mixture used was 80% CO2 and 20% i-C4H10 at a pressure of . We present the design of the chamber, the infrastructure and the performance during the 11 years of operation. The total radiation received on the anode wires was ~10-4 C/cm. No degradation of the anode pulse amplitude, wire efficiencies and resolution was observed for the whole running period.

Published
2003

69. Preliminary results from the prototype synchrotron radiation detector on space shuttle mission STS-108

Author

Y.-J Fanchiang, H. Hofer, J. Yang, Ayodhya N. Tiwari, M. Kräber, Zhuoxiang Ren, J Kuipers, T.-S Wang, T. Rauber, V. Commichau, J.R. Bates, B. Zimmermann, Felicitas Pauss, H. von Gunten, C. Camps, A. Lebedev, Gui Nyun Kim, M. Fritschi, H. Anderhub, Ulf Roser, K. Hangarter, Dong-Chul Son, Günter Flügge, W. Kästli, Samuel C.C. Ting, G. Viertel, Werner Lustermann, Manwoo Lee, R Kan, R. Lewis, K.S. Kim, S.C. Lee, G. Kenney, L. Djambazov, V. Koutsenko, Adrian Biland, D. Ren, M. Capell, Derk Bätzner, U. Horisberger, Oliver Grimm, S. Waldmeier Wicki, and S Baumgartner

Subjects
Physics, Nuclear and High Energy Physics, Physics::Instrumentation and Detectors, Astrophysics::High Energy Astrophysical Phenomena, Detector, Gamma ray, Astronomy, Synchrotron radiation, Cosmic ray, Atomic and Molecular Physics, and Optics, Particle detector, Synchrotron, law.invention, Nuclear physics, symbols.namesake, law, Van Allen radiation belt, High-energy X-rays, symbols
Abstract

A Synchrotron Radiation Detector measures synchrotron radiation emitted by high energetic particles in the earth magnetic field. This allows to identify cosmic ray electrons and positrons with energies in the TeV region. One possibility for such a detector outside the atmosphere uses YAP crystals to measure synchrotron photons with energies in the keV range. As such a detector can not distinguish between photons and electrons, the main problems are the diffuse cosmic ray gamma background and low energetic electrons in the vicinity of the earth. While the intensity of the diffuse gamma rays is known quite well, there exists limited knowledge about keV-electrons in low earth orbits. To measure these electrons a Prototype Synchrotron Radiation Detector (PSRD) was flown with Space Shuttle mission STS-108 (Dec.2001) and preliminary analysis of the data show very favorable results.

Published
2002

70. Design and construction of the prototype synchrotron radiation detector

Author

H. von Gunten, H. Anderhub, V. Koutsenko, R. Lewis, A. Lebedev, G. Viertel, Dong-Chul Son, C. Camps, Gui Nyun Kim, Y.-J Fanchiang, Samuel C.C. Ting, Ayodhya N. Tiwari, V. Commichau, Oliver Grimm, Adrian Biland, Felicitas Pauss, S.C. Lee, J Kuipers, K. Hangarter, T.-S Wang, Zhuoxiang Ren, J.R. Bates, M. Capell, D. Ren, S. Waldmeier Wicki, T. Rauber, B. Zimmermann, H. Hofer, Werner Lustermann, S Baumgartner, Derk Bätzner, Manwoo Lee, R Kan, U. Horisberger, K.-S. Kim, Ulf Roser, G. Kenney, Günter Flügge, J Yang, M. Fritschi, W. Kästli, L. Djambazov, and M. Kräber

Subjects
Physics, Nuclear and High Energy Physics, Spectrometer, business.industry, Astrophysics::High Energy Astrophysical Phenomena, Bremsstrahlung, Space Shuttle, Synchrotron radiation, Cosmic ray, Particle detector, Synchrotron, law.invention, Nuclear physics, Optics, law, Alpha Magnetic Spectrometer, business, Instrumentation
Abstract

The Prototype Synchrotron Radiation Detector (PSRD) is a small-scale experiment designed to measure the rate of low-energy charged particles and photons in near the Earth's orbit. It is a precursor to the Synchrotron Radiation Detector (SRD), a proposed addition to the upgraded version of the Alpha Magnetic Spectrometer (AMS-02). The SRD will use the Earth's magnetic field to identify the charge sign of electrons and positrons with energies above 1 TeV by detecting the synchrotron radiation they emit in this field. The differential energy spectrum of these particles is astrophysically interesting and not well covered by the remaining components of AMS-02. Precise measurements of this spectrum offer the possibility to gain information on the acceleration mechanism and characteristics of all cosmic rays in our galactic neighbourhood. The SRD will discriminate against protons as they radiate only weakly. Both the number and energy of the synchrotron photons that the SRD needs to detect are small. The identification is complicated by the presence of a large particle and photon background. Existing measurements of these backgrounds are insufficient for the construction of the large-scale SRD, so a measurement in space was indispensable. The PSRD was designed to fly as a Space Shuttle secondary payload, within the Shuttle Small Payloads Project. The flight on board the Space Shuttle Endeavour took place from 5 to 17 December 2001. The scientific goal, hardware and the flight of the PSRD are described in this report.

Published
2002

71. Testing of FE Hybrids and Si detector modules for the CMS Tracker

Author

M. Poettgens, F. Beissel, C.E.D Ilgin, V. Commichau, P. Schorn, C. Camps, W. Struczinski, T. Franke, J. Niehusmann, J. Mnich, Reinhard W. Schulte, G. Fluegge, and Markus Axer

Subjects
Physics, Nuclear and High Energy Physics, Silicon, business.industry, Interface (computing), Detector, chemistry.chemical_element, Tracking (particle physics), Particle detector, Semiconductor detector, Printed circuit board, chemistry, business, Instrumentation, Computer hardware, Graphical user interface
Abstract

The innermost region of the CMS detector will consist of silicon pixel and silicon microstrip detectors. One microstrip detector module is essentially composed of three elements: a set of silicon sensors, a mechanical support structure and the Front End Electronics (FE hybrid). During the production phase of the CMS tracking device, various quality and functionality tests of each detector component have to be performed to assure a stable tracker performance for a time scale of about 10 years of LHC running. This demands a chain of testing procedures beginning at the Hybrid component level and ending at the assembled module level. Each production and assembly step needs a specific testing environment and procedure (e.g. long- or short-term tests and temperature cyclings). A compact, cost efficient test and diagnostic tool which is suited for the operation and characterization of hybrids and silicon detector modules will be presented. The test setup is mainly composed of two printed circuit boards, one interface to the PC and the graphical user interface.

Published
2002

72. Impact on survival of pulmonary metastasectomy in colorectal cancer

Author

Alfonso Berrocal, C. Avila Andrade, C. Caballero Diaz, A.B. Fernandez Diaz, C. Camps Herrero, L.D. Condori Farfan, V. Iranzo Gonzalez-Cruz, A. Blasco Cordellat, I. Shaheen, A. Rodriguez Huaman, M.J. Safont Aguilera, M.C. Godes Sanz de Bremond, Vincenzo Sforza, A.J. Cunquero Tomas, M. Gil Raga, and M. Meri Abad

Subjects
Oncology, medicine.medical_specialty, business.industry, Colorectal cancer, Internal medicine, Medicine, Hematology, Metastasectomy, business, medicine.disease
Published
2017

73. Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer

Author

Eloisa Jantus-Lewintre, A. Moreno Manuel, S. Gallach Garcia, Ana Blasco, Miguel Martorell, A.J. Cunquero Tomas, A. Herreros Pomares, C. Camps Herrero, F. Aranda, S. Calabuig Fariñas, E. Carreras, and Francisco Lozano

Subjects
Oncology, business.industry, medicine, Cancer research, Hematology, Non small cell, Lung cancer, medicine.disease, business
Published
2017

74. Characterization of cancer stem cell and immune microenvironment interactions in non-small cell lung cancer (NSCLC)

Author

Susana Torres, A. Herreros-Pomares, E. García del Olmo, Eloisa Jantus-Lewintre, E. Escorihuela, M. Mosqueda, C. Aguilar, S. Calabuig Fariñas, C. Camps Herrero, and Rafael Sirera

Subjects
Oncology, medicine.medical_specialty, business.industry, Cancer stem cell, Internal medicine, Immune microenvironment, medicine, non-small cell lung cancer (NSCLC), Hematology, business, medicine.disease
Published
2017

75. Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study' NADIM trial

Author

M. Majem Tarruella, E. Nadal, N. Vinolas Segarra, D. Vicente Baz, I.C. Barneto Aranda, A. Insa Molla, M. Guillot Morales, M. Provencio Pulla, R. Bernabe Caro, J. de Castro, Guillermo Lopez-Vivanco, M. Domine Gomez, Jose-Luis Gonzalez-Larriba, J. Casal Rubio, A. Martinez Marti, M. Cobo Dols, B. Massuti Sureda, V. Calvo De Juan, D. Rodriguez Abreu, and C. Camps Herrero

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, medicine, Stage IIIA Non-Small Cell Lung Cancer, Hematology, business, Adjuvant, Chemo immunotherapy
Published
2017

76. Tumor microenvironment in high serous ovary cancer: Characterization of the infiltration pattern and analysis of its prognostic value

Author

F. Herrera Cañizares, M. Mosqueda, E. Jantus Lewintre, C. Camps Herrero, A. Chipirliu, L. Valdivieso, A. Herreros Pomares, C. Caballero, S. Calabuig Fariñas, J. Marí Alexandre, and J. Gilabert

Subjects
Pathology, medicine.medical_specialty, Serous fluid, Oncology, business.industry, medicine, Hematology, medicine.disease, business, Infiltration (medical), Ovary cancer
Published
2017

77. Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways

Author

C. Camps Herrero, Hector Amado, Atilio Navarro, A. Herreros Pomares, S. Gallach Garcia, E. Escorihuela, S. Calabuig Fariñas, Ricardo Guijarro, and Eloisa Jantus-Lewintre

Subjects
Oncology, business.industry, medicine, Cancer research, Hematology, Non small cell, Signal transduction, Differential expression, Lung cancer, medicine.disease, business
Published
2017

78. How do Spanish medical oncologists manage breakthrough pain? A national study

Author

A. Anton Torres, E. Aranda, Margarita Feyjoo, C. Camps Herrero, M. Constenla Figueiras, J. Garcia Foncillas, V. Guillem Porta, Alfredo Carrato, E. Diaz Rubio, Pere Gascón, J.J. Cruz Hernandez, Régulo López, and P. Khosravi

Subjects
medicine.medical_specialty, Oncology, business.industry, Breakthrough Pain, Physical therapy, medicine, National study, Hematology, business
Published
2017

80. Course diaphragmatique après bloc inter-sterno-cléido-mastoïdien, en fonction du site d'injection

Author

E Legendre, E Blanche, F Petitfaux, C Camps, Michel Pinaud, C Pham-Dang, and B Dupas

Subjects
Gynecology, medicine.medical_specialty, Diaphragmatic paresis, Anesthesiology and Pain Medicine, Surgical approach, business.industry, Regional anesthesia, Injection site, Medicine, General Medicine, business, Neck muscles
Abstract

Resume Objectif : Expliquer le caractere inconstant de la paresie hemidiaphragmatique apres bloc inter-sterno-cleido-mastoidien (inter-SCM). Type d'etude : Etude prospective, comparative, en simple aveugle. Patients : 16 patients de classe ASA 1–2. Methodes : Evaluation de la paresie diaphragmatique apres bloc inter-SCM par un radiologue ignorant la technique et le cote opere. Determination de la course diaphragmatique (CD) sur des cliches thoraciques pris en double exposition, en phases pre- et postoperatoires (CD pre, CD post) du cote homolateral et controlateral. Tous les patients ont recu un melange adrenaline de 20 mL de bupivacaine a 0,5 % et de 20 mL de lidocaine a 2 %, injecte par l'aiguille de stimulation, ou par le catheter, apres controle radiologique de sa position. Ils ont ete repartis en deux groupes equilibre. Groupe 1 : injection via l'aiguille apres obtention d'une flexion digitale a la stimulation, ou via le catheter en position infraclaviculaire ; groupe 2 : injection via l'aiguille apres contraction du deltoide ou du biceps, ou via le catheter en position susclaviculaire. Resultats : Tous les patients ont eu un bloc satisfaisant. Du cote opere, la course diaphragmatique etait diminuee apres realisation du bloc dans le groupe 2 ( P Conclusion : La paresie diaphragmatique est evitable si l'anesthesique local est injecte par l'aiguille apres obtention d'une flexion des doigts, ou par un catheter en position infraclaviculaire.

Published
2000

81. Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study

Author

C, Camps, E N, Martínez, A B, Jaime, and C C, Herrero

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Neutropenia, medicine.drug_class, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Pilot Projects, Vinblastine, Vinorelbine, Deoxycytidine, Antimetabolite, Gastroenterology, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Aged, Chemotherapy, Performance status, business.industry, Middle Aged, medicine.disease, Thrombocytopenia, Gemcitabine, Surgery, Treatment Outcome, Oncology, Female, Neoplasm Recurrence, Local, business, medicine.drug
Abstract

Purpose : This pilot study was designed to evaluate the efficacy and toxicity of the gemcitabine/vinorelbine combination in non-small-cell lung cancer (NSCLC) patients who had failed cisplatin-based first-line chemotherapy. Patients and methods : Eligible patients had refractory or resistant NSCLC, WHO performance status 0–2, adequate hematologic parameters and normal hepatic, renal and cardiac function. Gemcitabine (1200 mg/m 2 ) was administered on days 1, 8 and 15; vinorelbine (25 mg/m 2 ) was administered on days 1 and 8, every 4 weeks until patients experienced disease progression. Results : From September 1997 to March 1998, 16 patients were enrolled (six: stage IIIB; ten: stage IV). All 16 patients were assessable for toxicity and evaluated for response. One complete (6.25%) response and no partial responses were observed. Median survival was 25 weeks (95% CI, 19–30). A median of 3.31 courses per patient was administered, and the median interval between courses was 28 days. The median delivered dose was 664.85 mg/m 2 per week of gemcitabine and 10.71 mg/m 2 per week of vinorelbine, corresponding to a relative dose intensity of 0.73 and 0.85, respectively. Grade 2/3 thrombocytopenia occurred in 13 (24.52%) of 53 courses administered. Neutropenia Grade 2/3 occurred in 14 courses (26.41%). There were seven (13.20%) episodes of fever related to the drug administration. Mild asthenia was observed in six (37.5%) patients. Other toxicities were mild to moderate. Conclusion : These results suggest that this gemcitabine/vinorelbine combination is not an active salvage regimen in patients with refractory NSCLC. The combination merits further evaluation with modified regimens.

Published
2000

82. Cosmic-ray positron fraction measurement from 1 to 30 GeV with AMS-01

Author

Aguilar, M, Alcaraz, J, Allaby, J, Alpat, B, Ambrosi, G, Anderhub, H, L. Ao, A. Arefiev, P. Azzarello, L. Baldini, M. Basile, D. Barancourt, F. Barao, G. Barbier, G. Barreira, R. Battiston, R. Becker, U. Becker, L. Bellagamba, P. Béné, J. Berdugo, P. Berges, B. Bertucci, A. Biland, S. Blasko, Boschini, M, M. Bourquin, L. Brocco, G. Bruni, M. Buénerd, J. D. Burger, W. J. Burger, X. D. Cai, C. Camps, P. Cannarsa, M. Capell, F. Cardano, D. Casadei, J. Casaus, G. Castellini, Y. H. Chang, H. F. Chen, H. S. Chen, Z. G. Chen, N. A. Chernoplekov, T. H. Chiueh, K. Cho, M. J. Choi, Y. Y. Choi, F. Cindolo, V. Commichau, A. Contin, E. Cortina Gil, M. Cristinziani, T. S. Dai, C. Delgado, S. Difalco, L. Djambazov, I. D'Antone, Z. R. Dong, P. Emonet, J. Engelberg, F. J. Eppling, T. Eronen, G. Esposito, P. Extermann, J. Favier, E. Fiandrini, P. H. Fisher, G. Flügge, N. Fouque, Y.u. Galaktionov, H. Gast, P. Giusti, Grandi, D, O. Grimm, W. Q. Gu, K. Hangarter, A. Hasan, V. Hermel, H. Hofer, W. Hungerford, M. Jongmanns, K. Karlamaa, W. Karpinski, G. Kenney, D. H. Kim, G. N. Kim, K. S. Kim, M. Y. Kim, A. Klimentov, R. Kossakowskic, A. Kouninel, V. Koutsenkol, M. Kraeberai, G. Laboriet, T. Laitinenah, G. Lamannaad, 1, E. Lanciottiz, G. Laurentij, A. Lebedevl, C. Lechanoine Lelucs, M. W. Leeo, S. C. Leeag, G. Levij, C. L. Liuy, H. T. Liui, G. Lug, Y. S. Lui, K. Lübelsmeyera, D. Luckeyl, W. Lustermannai, C. Mañaz, A. Margottij, F. Mayett, R. R. McNeild, B. Meillont, M. Menichelliad, A. Mihulk, A. Mujunenv, A. Olivaad, J. Olzema, F. Palmonarij, H. B. Parko, W. H. Parko, M. Pauluzziad, F. Paussai, E. Perrins, A. Pescij, A. Pevsnere, F. Piloae, M. Pimentax, w, V. Plyaskinac, V. Pojidaevac, M. Pohls, N. Produits, Rancoita, PG D. Rapins, F. Raupacha, D. Renai, Z. Renag, M. Ribordys, J. P. Richeuxs, E. Riihonenah, J. Ritakariv, S. Roo, U. Roeserai, C. Rossint, R. Sagdeevn, D. Santost, G. Sartorellij, C. Sbarraj, S. Schaela, A. Schultz von Dratziga, G. Schweringa, E. S. Seon, J. W. Shino, E. Shoumilovac, V. Shoutkol, T. Siedenburgl, R. Siedlinga, D. Sono, T. Songh, F. Spinellaae, M. Steuerl, G. S. Sunh, H. Suterai, X. W. Tangi, Samuel C. C. Tingl, S. M. Tingl, M. Tornikoskiv, J. Torstiah, J. Trümperq, J. Ulbrichtai, S. Urpov, E. Valtonenah, J. Vandenhirtza, E. Velikhovab, B. Verlaatai, 2, I. Vetlitskyac, F. Vezzut, J. P. Viallec, G. Viertelai, D. Vités, H. Von Guntenai, S. Waldmeier Wickiai, W. Wallraffa, B. C. Wangy, J. Z. Wangg, K. Wiikv, C. Williamsj, S. X. Wul, m, P. C. Xiah, S. Xul, J. L. Yang, L. G. Yanh, C. G. Yangi, J. Yangaf, M. Yangi, S. W. Yeu, 3, Z. Z. Xu, H. Y. Zhang, Z. P. Zhang, D. X. Zhao, Y. Zhou, G. Y. Zhu, W. Z. Zhu, H. L. Zhuang, A. Zichichi, B. Zimmermann, P. Zuccon, BOELLA, GIULIANO FILIPPO, GERVASI, MASSIMO, Bene, Pierre, Bourquin, Maurice, Cortina Gil, Eduardo, Cristinziani, Markus, Emonet, Pascal Philippe, Extermann, Pierre, Leluc, Catherine, Perrin, Eric, Pohl, Martin, Produit, Nicolas, Rapin, Divic Jean, Ribordy, Mathieu, Richeux, Jean-Pierre, Vite, Davide, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), AMS, M. AGUILAR, J. ALCARAZ, J. ALLABY, B. ALPAT, G. AMBROSI, H. ANDERHUB, L. AO, A. AREFIEV, P. AZZARELLO, L. BALDINI, M. BASILE, D. BARANCOURT, F. BARAO, G. BARBIER, G. BARREIRA, R. BATTISTON, R. BECKER, U. BECKER, L. BELLAGAMBA, P. BENE, J. BERDUGO, P. BERGES, B. BERTUCCI, A. BILAND, S. BLASKO, G. BOELLA, M. BOSCHINI, M. BOURQUIN, L. BROCCO, G. BRUNI, M. BUENERD, J.D. BURGER, W.J. BURGER, X.D. CAI, C. CAMPS, P. CANNARSA, M. CAPELL, F. CARDANO, D. CASADEI, J. CASAUS, G. CASTELLINI, Y.H. CHANG, H.F. CHEN, H.S. CHEN, Z.G. CHEN, N.A. CHERNOPLEKOV, T.H. CHIUEH, K. CHO, M.J. CHOI, Y.Y. CHOI, F. CINDOLO, V. COMMICHAU, A. CONTIN, E. CORTINA-GIL, M. CRISTINZIANI, T.S. DAI, C. DELGADO, S. DIFALCO, L. DJAMBAZOV, I. D'ANTONE, Z.R. DONG, P. EMONET, J. ENGELBERG, F.J. EPPLING, T. ERONEN, G. ESPOSITO, P. EXTERMANN, J. FAVIER, E. FIANDRINI, P.H. FISHER, G. FLUEGGE, N. FOUQUE, YU. GALAKTIONOV, H. GAST, M. GERVASI, P. GIUSTI, D. GRANDI, O. GRIMM, W.Q. GU, K. HANGARTER, A. HASAN, V. HERMEL, H. HOFER, W. HUNGERFORD, M. JONGMANNS, K. KARLAMAA, W. KARPINSKI, G. KENNEY, D.H. KIM, G.N. KIM, K.S. KIM, M.Y. KIM, A. KLIMENTOV, R. KOSSAKOWSKI, A. KOUNINE, V. KOUTSENKO, M. KRAEBER, G. LABORIE, T. LAITINEN, G. LAMANNA, E. LANCIOTTI, G. LAURENTI, A. LEBEDEV, C. LECHANOINE-LELUC, M.W.LEE, S.C. LEE, G. LEVI, C.L. LIU, H.T. LIU, G. LU, Y.S. LU, K. LUBELSMEYER, D. LUCKEY, W. LUSTERMANN, C. MANA, A. MARGOTTI, F. MAYET, R.R. MCNEIL, B. MEILLON, M. MENICHELLI, A.MIHUL, A. MUJUNEN, A. OLIVA, J. OLZEM, F. PALMONARI, H.B. PARK, W.H. PARK, M. PAULUZZI, F. PAUSS, E. PERRIN, A. PESCI, A. PEVSNER, F. PILO, M. PIMENTA, V. PLYASKIN, V. POJIDAEV, M. POHL, N. PRODUIT, P.G. RANCOITA, D. RAPIN, F. RAUPACH, D. REN, Z. REN, M. RIBORDY, J.P. RICHEAUX, E. RIIHONEN, J. RITAKARI, S. RO, U. ROESER, C. ROSSIN, R. SAGDEEV, D. SANTOS, G. SARTORELLI, C. SBARRA, S. SCHAEL, A. SCHULTZ VON DRATZIG, G. SCHWERING, E.S. SEO, J.W. SHIN, E. SHOUMILOV, V. SHOUTKO, T. SIEDENBURG, R. SIEDLING, D. SON, T. SONG, F. SPINELLA, M. STEUER, G. S. SUN, H. SUTER, X.W. TANG, SAMUEL C.C. TING, S.M. TING, M. TORNIKOSKI, J. TORSTI, J. TRUEMPER, J. ULBRICHT, S. URPO, E. VALTONEN, J. VANDENHIRTZ, E. VELIKHOV, B. VERLAAT, I. VETLITSKI, F. VEZZU, J.P. VIALLE, G. VIERTEL, D. VITE, H. VON GUNTEN, S. WALDMEIER WICKI, W. WALLRAFF, B.C. WANG, J.Z. WANG, K. WIIK, C. WILLIAMS, S.X. WU, P.C. XIA, S. XU, J.L. YAN, L.G. YAN, C.G. YANG, J. YANG, M. YANG, S.W. YE, Z.Z. XU, H.Y. ZHANG, Z.P. ZHANG, D.X. ZHAO, Y. ZHOU, G.Y.ZHU, W.Z. ZHU, H.L. ZHUANG, A. ZICHICHI, B. ZIMMERMANN, P. ZUCCON, Aguilar, M, Alcaraz, J, Allaby, J, Alpat, B, Ambrosi, G, Anderhub, H, L., A, A., A, P., A, L., B, M., B, D., B, F., B, G., B, R., B, U., B, P., B, J., B, B., B, A., B, S., B, Boella, G, Boschini, M, J. D., B, W. J., B, X. D., C, C., C, P., C, M., C, F., C, D., C, J., C, G., C, Y. H., C, H. F., C, H. S., C, Z. G., C, N. A., C, T. H., C, K., C, M. J., C, Y. Y., C, V., C, A., C, E., C, T. S., D, C., D, S., D, L., D, I., D, Z. R., D, P., E, J., E, F. J., E, T., E, G., E, J., F, E., F, P. H., F, G., F, N., F, Galaktionov, Y, H., G, Gervasi, M, P., G, Grandi, D, O., G, W. Q., G, K., H, A., H, V., H, H., H, W., H, M., J, K., K, W., K, G., K, D. H., K, G. N., K, K. S., K, M. Y., K, A., K, R., K, V., K, Ac, M., K, G., L, T., L, E., L, A., L, C., L, M. W., L, S. C., L, C. L., L, H. T., L, Y. S., L, K., L, D., L, W., L, C., M, A., M, F., M, R. R., M, B., M, M., M, A., O, J., O, F., P, H. B., P, W. H., P, M., P, E., P, A., P, W, V., P, N., P, Rancoita, PG D., R, F., R, D., R, Z., R, M., R, J. P., R, E., R, J., R, S., R, U., R, C., R, R., S, D., S, G., S, C., S, S., S, A., S, E. S., S, J. W., S, E., S, V., S, T., S, F., S, M., S, G. S., S, H., S, X. W., T, Samuel C. C., T, S. M., T, M., T, J., T, J., U, S., U, E., V, J., V, B., V, I., V, F., V, J. P., V, G., V, D., V, H., V, S., W, W., W, B. C., W, J. Z., W, K., W, C., W, S. X., W, M, P. C., X, S., X, J. L., Y, L. G., Y, C. G., Y, J., Y, M., Y, S. W., Y, Z. Z., X, H. Y., Z, Z. P., Z, D. X., Z, Y., Z, G. Y., Z, W. Z., Z, H. L., Z, A., Z, B., Z, P., Z, and UCL - SST/IRMP - Institut de recherche en mathématique et physique

Subjects
Raggi cosmici, esperimento AMS, Nuclear and High Energy Physics, Astrophysics and Astronomy, Photon, Proton, Astrophysics::High Energy Astrophysical Phenomena, Cosmic ray, ddc:500.2, Astrophysics, 01 natural sciences, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Nuclear physics, FIS/05 - ASTRONOMIA E ASTROFISICA, Positron, 0103 physical sciences, 010306 general physics, Nuclear Experiment, Physics, Range (particle radiation), 010308 nuclear & particles physics, Bremsstrahlung, Order (ring theory), Cosmic Rays Positrons, AMS experiment, Physics::Accelerator Physics, FIS/04 - FISICA NUCLEARE E SUBNUCLEARE, Energy (signal processing)
Abstract

A measurement of the cosmic ray positron fraction e+ / (e+ + e-) in the energy range of 1-30 GeV is presented. The measurement is based on data taken by the AMS-01 experiment during its 10 day Space Shuttle flight in June 1998. A proton background suppression on the order of 106 is reached by identifying converted bremsstrahlung photons emitted from positrons., Physics Letters B, 646 (4), ISSN:0370-2693, ISSN:0031-9163, ISSN:1873-2445

Published
2007

83. Large scale test of wedge shaped micro strip gas counters

Author

J.-M. Brom, C. Vander Velde, V. Nagaslaev, T. Beckers, Piero Giorgio Verdini, R. Metri, G. Smadja, V. Zhukov, D. Pandoulas, W. Van Doninck, F. Udo, Oliver Pooth, B. Schwaller, J. Croix, S. Barthe, S. Bachmann, G. Schuster, P. Schmitz, Amina Zghiche, Bruno Wittmer, C. Hoffman, Hans-Jürgen Simonis, Rasmus Ischebeck, C. Camps, S. Weseler, J.M Helleboid, Pascal Vanlaer, K. Lübelsmeyer, H. Szczesny, K. Bernier, V. Chorowicz, K. Hangarter, W.H. Thümmel, S. Tissot, M. Hoffer, Th. Müller, A. Schultz von Dratzig, V. Commichau, E. Ruoff, Abdenour Lounis, T. Todorov, A. Bondar, C. Racca, J. P. Coffin, Fabien Jeanneau, W. Geist, W. Beaumont, I. Boulogne, Günter Flügge, Laurent Mirabito, Reinhard W. Schulte, S. Atz, R. Siedling, M. Bozzo, M. R. Kapp, Y. Benhammou, D. Neuberger, M. Krauth, C. Maazouzi, A. Sauer, Jean-Charles Fontaine, A. Pallares, D. Huss, V. Titov, D. Knoblauch, M. Tonutti, J. Kremp, J.P. Schunk, K. Kärcher, M. Petertill, Th. Henkes, F. Beißel, Pierre Juillot, Othmane Bouhali, J. Stefanescu, Ch.Van Dyck, D. Macke, H. Eberlé, P. Blüm, L. Shektman, R. Wortmann, Ulrich Goerlach, Didier Contardo, F. Drouhin, S. Junghans, M. Ackermann, M. Kräber, V. Aulchenko, K. Gundlfinger, Andreas Nowack, J. De Troy, A. M. Bergdolt, L. Van Lancker, M.-H. Sigward, Aysen Tatarinov, I. Ripp, B. Baiboussinov, and R. Haroutunian

Subjects
Physics, Nuclear and High Energy Physics, Large Hadron Collider, Muon, Physics::Instrumentation and Detectors, business.industry, Detector, Wedge (geometry), Gaseous particle detectors, Particle detector, Chemistry, Optics, Measuring instrument, High Energy Physics::Experiment, business, Engineering sciences. Technology, Instrumentation, Image resolution, Beam (structure)
Abstract

In order to check the system aspects of the forward-backward MSGC tracker designed for the future CMS experiment at LHC: 38 trapezoidal MSGC counters assembled in six multi-substrates detector modules were built and exposed to a muon beam at the CERN SPS. Results on the gain uniformity along the wedge-shaped strip pattern and across the detector modules are shown together with measurements of the detection efficiency and the spatial resolution. (C) 1999 Elsevier Science B.V. All rights reserved.

Published
1999

84. Construction, test and operation in a high intensity beam of a small system of micro-strip gas chambers

Author

Archana Sharma, Bożena Boimska, André Braem, O. Runolfsson, M. Capeans, C. Wolff, R. Bouclier, C. Camps, Günter Flügge, W. Dominik, J.-C Labbé, V. Commichau, V. Nagaslaev, M. Hoch, Frans Meijers, Lev Shekhtman, Alan Barr, M. Schulz, S. Bachmann, Faustino Gómez, Fabio Sauli, G. Manzin, R. Hammarström, K. Muhlemann, K. Hangarter, A. Peisert, Leszek Ropelewski, Reinhard W. Schulte, G. Million, and D. Macke

Subjects
Physics, Nuclear and High Energy Physics, Borosilicate glass, business.industry, Continuous monitoring, Detector, STRIPS, engineering.material, law.invention, Optics, Coating, law, engineering, Electronics, Detectors and Experimental Techniques, business, Instrumentation, Intensity (heat transfer), Beam (structure)
Abstract

We describe the construction, test and installation procedures, and the experience gained with the operation of a small but complete system of high-rate Micro-Strip Gas Chambers, made on thin borosilicate glass with a diamond-like coating with chromium or gold strips. A set of detectors, fully equipped with read-out electronics and each with an active area of 100 × 100 mm 2 , was exposed during six months to a high-intensity muon beam at CERN with a peak intensity of ∼ 10 4 mm −2 s −1 . Continuous monitoring of the performance of the chambers during the beam runs allowed the evaluation of detection efficiency and the monitoring of accidental rates, as well as the study of ambient induced variations and aging in realistic beam conditions. No significant difference has been found in the operation of under-and over-coated plates. Efficiencies could reach ∼ 98% in best operating conditions, although local lower values were often observed due to missing channels (open strips, broken bonds and dead electronic channels). The long-term operation of the chambers has been more difficult than expected, with the appearance of break-downs and loss of efficiency in some detectors, possibly induced by the presence of small gas leaks, to water permeation or to residual reactivity of the quencher gas (dimethylether).

Published
1998

85. Factores de riesgo y enfermedad cardiovascular en diabéticos tipo 2 de diagnóstico reciente

Author

Eduardo Valdés Ramos, María del C Camps Arjona, and Raúl Verdecia Saborit

Subjects
type 2 diabetes mellitus, risk factors, cardiovascular disease, Medicine (General), R5-920
Abstract

Objetivo: identificar los factores de riesgo y la frecuencia de enfermedad cardiovascular en personas con diabetes mellitus tipo 2 de diagnóstico reciente. Métodos: se realizó un estudio transversal y descriptivo con pacientes ingresados en el Centro de Atención al Diabético de Bayamo, Granma, en el período comprendido entre enero del 2011 a julio del 2012. El universo de estudio estuvo constituido por los 683 pacientes que ingresaron durante esa etapa en la institución. Representaron la muestra los 150 diabéticos tipo 2 que tenían menos de 6 meses de haber sido diagnosticados. Resultados: el 100 % de los pacientes presentaron, al menos, un factor de riesgo cardiovascular, los de mayor prevalencia fueron: el sobrepeso y la obesidad 135 casos (90,0 %), el síndrome metabólico 100 (66,6 %) y la hipertensión arterial, 99 (66,0 %). Al momento del diagnóstico, 24 (16 %) pacientes presentaron enfermedad cardiovascular: 11 (7,3 %) Cardiopatía isquémica, 4 (2,6 %) Ictus y 13 (8,6 %) Enfermedad arterial periférica. A cuatro de ellos, se le detectó más de una complicación. Conclusiones: la frecuencia de factores de riesgo en los diabéticos tipo 2 del territorio es elevada. Esta afirmación puede explicar que un porcentaje significativo de casos ya presenten complicaciones cardiovasculares al momento del diagnóstico.

86. Características clínicas y frecuencia de complicaciones crónicas en personas con diabetes mellitus tipo 2 de diagnóstico reciente

Author

Eduardo Valdés Ramos and Maria del C Camps Arjona

Subjects
Diabetes Mellitus tipo 2, complicaciones crónicas, hipertensión arterial, Medicine (General), R5-920
Abstract

Introducción: la caracterización clínica de las personas con diabetes es esencial para efectuar su evaluación de forma integral y ofrecer un tratamiento médico individualizado. Objetivo: identificar las características clínicas y la frecuencia de complicaciones crónicas en personas con Diabetes Mellitus tipo 2 de diagnóstico reciente en la provincia Granma. Métodos: se realizó un estudio transversal y descriptivo con pacientes diabéticos tipo 2 ingresados en el Centro de Atención al Diabético de Bayamo, Granma, en el período comprendido entre enero de 2011 a julio de 2012. El universo estuvo constituido por los 683 pacientes que ingresaron durante esa etapa en la institución. Representaron la muestra los 150 diabéticos tipo 2 que tenían menos de 6 meses de padecer la enfermedad. Resultados: la edad media fue de 49,2 años. Predominaron los diabéticos con antecedentes familiares de Diabetes Mellitus (60,6 %), con sobrepeso y obesidad (90 %) e hipertensos (62 %). Al momento del diagnóstico 43 (28,7 %) casos presentaron complicaciones crónicas: 9 (6 %) retinopatía diabética, 16 (10,6 %) polineuropatía diabética, 11 (7,3 %) cardiopatía isquémica, 4 (2,6 %) ictus y 13 (8,6 %) enfermedad arterial periférica. A 7 pacientes se les diagnosticó más de una complicación. Conclusiones: la Diabetes Mellitus tipo 2 frecuentemente se presenta en nuestro medio en personas mayores de 45 años, con antecedentes familiares de diabetes y asociada a la obesidad y la hipertensión arterial. Las complicaciones crónicas de la diabetes están presentes en un porcentaje elevado de casos al momento del diagnóstico inicial de dicha enfermedad.

87. The readout and DAQ system of the L3 silicon microstrip detector

Author

A. Bay, Roberto Battiston, M. Acciarri, D. M. Lee, M. Sachwitz, O. Adriani, G. Castellini, Giovanni Ambrosi, G. Landi, G. M. Bilei, V. Commichau, P. Extermann, R. Leiste, J. S. Kapustinsky, R. Siedling, P. Schmitz, A. Gabbanini, C. Camps, G. Terzi, S. Pensotti, F. Tonisch, G. Trowitzsch, B. Schöneich, M. Tesi, Wolfgang Lohmann, H. Vogt, B. Bertucci, G. Passaleva, K. Hangarter, G.B. Mills, M. L. Brooks, M. Bosetti, T. E. Coan, B. Checcucci, M. Rattaggi, Roberto Castello, Andrea Baschirotto, W. J. Burger, W. W. Kinnison, P. G. Rancoita, and H. Nowak

Subjects
Physics, Nuclear and High Energy Physics, Data acquisition, Physics::Instrumentation and Detectors, business.industry, Detector, Optoelectronics, High Energy Physics::Experiment, business, Instrumentation, Silicon microstrip detectors
Abstract

In 1993 the L3 detector at LEP has been equipped with a Silicon Microstrip Detector (SMD). In this paper we give a full description of the various components of the SMD readout and DAQ system.

Published
1995

88. Lateral Elbow Pain

Author

C. Camps

Subjects
medicine.medical_specialty, business.industry, Physical therapy, Medicine, business, Elbow pain
Published
2011

89. Compression of the Ulnar Nerve

Author

A. Lahiri, A. Y. T. Lim, and C. Camps

Subjects
business.industry, Medicine, Anatomy, Ulnar nerve, Compression (physics), business
Published
2011

90. Construction and performance of the L3 central tracking detector

Author

H. von Gunten, J. Ulbricht, Dimitri Bourilkov, Hannes Jung, H. Anderhub, S. Botev, J. Herrmann, P. Göttlicher, W. Friebel, M. Sassowsky, P. Zemp, J.P. Richeux, Stefan Kirsch, G. Forconi, W. Kastli, R. Leiste, J. Spangler, R. Krankenhagen, P. Schmitz, Y. Peng, M. Deutschmann, M. Hänsli, Ryan Heller, C. Camps, C. Spartiotis, Adrian Biland, F. Beauvais, F. Masciocchi, U. Herten, M. J. Glaubman, M. Möller, Georgi Sultanov, Joe D. Orndorff, F. Tonisch, H. Thürig, Marc Weber, T. Spickermann, P. Bene, Lucas Taylor, M. Pohl, L. Djambazov, G. Barbier, J.C. Sens, B. L. Betev, H. Szczesny, D. McNally, D. Newman, M. Wilhelmi, E. Perrin, M. Maolinbay, A. Donat, D.M. Jansen, G. Viertel, W. Baur, E. Haerdi, M. Tonutti, George Alverson, T. Winands, Wolfgang Lohmann, H. Vogt, U. Rinsche, K. Hangarter, I. Leedom, H. Hofer, J. Grooten, R. Starosta, D. La Marra, D. Ren, H. Frohn, S. Reucroft, F. Behner, Reinhard W. Schulte, A. Pevsner, S. Röhner, Ph Fisher, P. Vikas, H. Schuijlenburg, E. Isiksal, F. Beissel, H. Virnich, A. Böhm, M. Dhina, D. J. Schotanus, Nicolas Produit, L. Antonov, S. Waldmeier, N. Rieb, K. Lanius, Wolfgang Lange, V.R. Krastev, H. Liebmann, C. Neyer, J. Perrier, J. Fehlmann, Werner Lustermann, G. Rahal-Callot, A. Leger, K. Schultze, H. Suter, M. Bourquin, W. Reuter, J. Weber, B. Stöhr, I. Orlinov, H. Akbari, K. Quadflieg, S. Schulte, J. Mnich, U. Horisberger, J. Bao, A. Gougas, K. Bosseler, L. Zehnder, J. Behrens, Konrad Deiters, X. Lue, Jérôme Rose, Ulf Roser, J. H. Field, G. Trowitzsch, C. Y. Chien, R. Pahlke, V. Commichau, M. Okle, and A. Hasan

Subjects
Physics, Nuclear and High Energy Physics, Drift velocity, Physics::Instrumentation and Detectors, Expansion chamber, business.industry, TEC, Detector, Tracking (particle physics), Nuclear physics, Optics, Data acquisition, Large Electron–Positron Collider, High Energy Physics::Experiment, business, Instrumentation, Image resolution
Abstract

The L3 central tracking detector has been in operation since the start-up of LEP (Large Electron Positron collider) in 1989. This detector consists of a Time Expansion Chamber (TEC), a layer of Plastic Scintillating Fibers and a Z-chamber. The TEC gives a high spatial resolution and an excellent multi-track reconstruction capability. The fibers are designed to calibrate the drift velocity with high precision. The Z-Chamber provides TEC with accurate information about the z-coordinates of the tracks. A description of the design and the infrastructure of these three detectors, including the readout and data acquisition system, is given. The performance of the detectors during the 1990 and 1991 LEP running periods is presented.

Published
1993

91. [Pharmacoeconomics and cost of cancer drugs]

Author

C, Camps Herrero, C, Caballero Díaz, and A, Blasco Cordellat

Subjects
Spain, Cost-Benefit Analysis, Neoplasms, Humans, Antineoplastic Agents, Economics, Pharmaceutical, Drug Costs
Abstract

Cancer is a disease of high incidence, which determines that the health systems will be forced to allocation a significant amount of resources. In an era of evidence-based medicine and increasing cost pressures, it is important to understand the relative clinical and economic impact of the many drug treatment strategies available for cancer patients. Currently, resources that may be spent in pharmacoeconomics expenditure are limited so it is necessary to rationalize their consumption and priorize in the allocation of these resources to the options with higher economic advantages. Pharmacoeconomic studies will permit us to know what is the efficiency of different therapeutic alternatives so they will help to determine the therapeutic options that we should use in routine medical practice.

Published
2010

92. [Consensus document on the use of granulocyte colony stimulating factor biosimilars for correction of neutropenia in cancer patients]

Author

E, Aranda Aguilar, C, Camps Herrero, A, Carrato Mena, A, Clopés Estela, J J, Cruz Hernández, O, Delgado Sánchez, E, Díaz-Rubio García, A, Domínguez-Gil Hurlé, B, Dorantes Calderón, P, García Alfonso, and A, Herrero Ambrosio

Subjects
Europe, Consensus, Neutropenia, Neoplasms, Humans, Antineoplastic Agents, Pharmacy Service, Hospital, Biosimilar Pharmaceuticals
Published
2010

93. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer]

Author

E, Rodríguez-Murphy, S, Villanueva-Herraiz, M P, Ortega-García, A, Pérez-Feliu, M A, López-Montenegro Soria, and C, Camps-Herrero

Subjects
Adult, Aged, 80 and over, Male, Antibodies, Monoclonal, Cetuximab, Antineoplastic Agents, Middle Aged, Antibodies, Monoclonal, Humanized, Acneiform Eruptions, Humans, Female, Drug Eruptions, Neoplasm Metastasis, Colorectal Neoplasms, Aged, Retrospective Studies
Abstract

To evaluate the impact and type of side-effects in patients treated with cetuximab and provide a description of the general measures and treatment.Retrospective safety study. We included all patients that received cetuximab from January to December 2009. All information was obtained from the Pharmacy and Oncology Department's Access databases and reviewed the patient's medical history. All data was registered in an Excel workbook. Skin toxicity was graded by the current National Cancer Institute-Common Toxicity Criteria (NCI-CTC).During the study period 43 patients received treatment with cetuximab. Acneiform eruption was present in 30 of the cases (69.8%): 14 patients with grade 1 (48.3%), 13 with grade 2 (44.8%) and 3 with grade 3 (10.3%). These adverse effects appeared in a median of seven (4-28) days. In a median of 40 (20-56) days, ten patients (23.3%) presented xerosis, and three (7%) suffered painful fissures in hands and feet after a median of 28 (21-35) days. Paronychia was present in two patients after a median of 42 (35-49) days. Finally, an alteration in hair growth was observed in two patients with overgrowth of facial hair and one patient with overgrowth of the eyelashes. Five patients presented important conjunctivitis. Three infusion reactions occurred. A grade-based treatment algorithm was used for all patients that presented cutaneous toxicity.A considerable number of patients treated with cetuximab develop dermatological side-effects which left untreated could represent a threat to the efficacy of the therapy. Therefore effective management is mandatory, patient education and immediate treatment based on a grade-based algorithm to alleviate symptoms is necessary, so that patient compliance is guaranteed.

Published
2010

94. The L3 vertex detector: design and performance

Author

U. Herten, J. Mnich, J. Bao, R. Leiste, Georgi Sultanov, H. Anderhub, C. Spartiotis, P. Vikas, Ryan Heller, F. Tonisch, M. Glaubman, P. Zemp, G. Rahal-Callot, J.C. Sens, J. Behrens, H. von Gunten, A. Pevsner, J. Ulbricht, Ph Fisher, K. Schultze, H. Suter, S. Reucroft, L. Taylor, Hannes Jung, M. Pohl, C. Neyer, Y. Peng, P. Göttlicher, K. Quadleig, B. L. Betev, George Alverson, T. Winands, K. Dieters, W. Freibel, Wolfgang Lohmann, H. Vogt, D. Newman, J. Spangler, P. Schmitz, K. Hangarter, C. Camps, R. Starosta, T. Spickermann, Reinhard W. Schulte, Joe D. Orndorff, D. Ren, H. Virnich, V. Commichau, U. Rinsche, Ulf Roser, A. Hasan, N. Rieb, I. Leedom, Adrian Biland, A. Böhm, M. MacDermott, H. Liebmann, Jérôme Rose, G. Trowitzsch, C. Y. Chien, H. Hofer, A. Donat, M. Haensli, M. Möller, F. Behner, F. Beissel, J. Weber, D. McNally, G. Viertel, S. Röhner, H. Akbari, S. Waldmeier, H. Szcesny, L. Djambazov, and M. Maolinbay

Subjects
Physics, Nuclear and High Energy Physics, Luminosity (scattering theory), Drift velocity, Physics::Instrumentation and Detectors, Expansion chamber, business.industry, TEC, Data acquisition, Optics, High Energy Physics::Experiment, Vertex detector, business, Instrumentation, Image resolution
Abstract

The L3 vertex detector is comprised of the time expansion chamber (TEC), the Z -chamber and a layer of plastic scintillating fibers. The TEC has shown a high spatial resolution and an excellent multi-track reconstruction capability at LEP luminosity. The Z -chamber provides information about the z -coordinates of the tracks and the fibers are used for calibrating the drift velocity with a high precision. A description of the L3 vertex detector, its readout and data acquisition and its performance during the 1990 LEP running period is presented in this paper.

Published
1992

95. [Study of use of pemetrexed in non-small cell lung cancer]

Author

S, Villanueva-Herraiz, M P, Ortega-García, C, Camps-Herrero, and P, Blasco-Segura

Subjects
Adult, Male, Antimetabolites, Antineoplastic, Guanine, Lung Neoplasms, Smoking, Kaplan-Meier Estimate, Pemetrexed, Adenocarcinoma, Middle Aged, Hospital Records, Treatment Outcome, Glutamates, Carcinoma, Non-Small-Cell Lung, Oncology Service, Hospital, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Drug Evaluation, Humans, Female, Pharmacy Service, Hospital, Aged, Retrospective Studies
Abstract

To study the effectiveness and safety of pemetrexed in non-small cell lung cancer.Retrospective study (March 2006-May 2008) of pemetrexed use. Information was obtained from the Access database belonging to the Pharmacy and Oncology Departments, the registry of external consultations and clinical histories. Data were analysed using SPSS software version 12.0. Quantitative variables are expressed as the median (minimum-maximum).The study included 44 patients (61.7 [39-77] years old), mostly male (86%), smokers or former smokers (80%) with predominantly epidermoid/squamous disease (46%) or adenocarcinoma, in a good functional state (86%) and in stageor =III upon beginning pemetrexed treatment (93%). Prior treatment with taxanes and taxane treatment along with a prior history of neutropoenia were the criteria for changing to pemetrexed in 34.4% and 22.7% of the patients, respectively. None of the patients presented a complete or partial response: 18.2% showed disease stability and 81.8% showed disease progression. The main reasons for discontinuing pemetrexed were progression of the disease (54.5%) and worsening of symptoms (15.9%). Median survival after beginning chemotherapy was 22.2 months (ranging from 16-28.4) and 7.8 months (4.4-11.2) after beginning pemetrexed treatment. These last figures were significantly higher in women and those with an ECOG of 0 to 1. The most common adverse effects were weakness and neurotoxicity.In each of the cases, pemetrexed was used as a second-line treatment or higher with a good safety profile. A complete or partial response was not reached in any of the cases, but survival after beginning pemetrexed was equal to or longer than that achieved in other studies.

Published
2009

96. A measurement of mixing in Z0 decays

Author

B. Adeva, O. Adriani, M. Aguilar-Benitez, H. Akbari, J. Alcaraz, A. Aloisio, G. Alverson, M.G. Alviggi, Q. An, H. Anderhub, A.L. Anderson, V.P. Andreev, T. Angelov, L. Antonov, D. Antreasyan, P. Arce, A. Arefiev, T. Azemoon, T. Aziz, P.V.K.S. Baba, P. Bagnaia, J.A. Bakken, L. Baksay, R.C. Ball, S. Banerjee, J. Bao, L. Barone, A. Bay, U. Becker, J. Behrens, S. Beingessner, Gy.L. Bencze, J. Berdugo, P. Berges, B. Bertucci, B.L. Betev, A. Biland, R. Bizzarri, J.J. Blaising, P. Blömeke, B. Blumenfeld, G.J. Bobbink, M. Bocciolini, W. Böhlen, A. Böhm, T. Böhringer, B. Borgia, D. Bourilkov, M. Bourquin, D. Boutigny, B. Bouwens, J.G. Branson, I.C. Brock, F. Bruyant, C. Buisson, A. Bujak, J.D. Burger, J.P. Burq, J. Busenitz, X.D. Cai, C. Camps, M. Capell, F. Carbonara, F. Carminati, A.M. Cartacci, M. Cerrada, F. Cesaroni, Y.H. Chang, U.K. Chaturvedi, M. Chemarin, A. Chen, C. Chen, G.M. Chen, H.F. Chen, H.S. Chen, M. Chen, M.C. Chen, M.L. Chen, G. Chiefari, C.Y. Chien, F. Chollet, C. Civinini, I. Clare, R. Clare, H.O. Cohn, G. Coignet, N. Colino, V. Commichau, G. Conforto, A. Contin, F. Criins, X.Y. Cui, T.S. Dai, R. D'Alessandro, R. de Asmundis, A. Degré, K. Deiters, E. Dénes, P. Denes, F. DeNotaristefani, M. Dhina, D. DiBitonto, M. Diemoz, F. Diez-Hedo, H.R. Dimitrov, C. Dionisi, F. Dittus, R. Dolin, E. Drago, T. Driever, D. Duchesneau, P. Duinker, I. Duran, H. El Mamouni, A. Engler, F.J. Eppling, F.C. Erné, P. Extermann, R. Fabbretti, G. Faber, S. Falciano, Q. Fan, S.J. Fan, M. Fabre, O. Fackler, J. Fay, J. Fehlmann, H. Fenker, T. Ferguson, G. Fernandez, F. Ferroni, H. Fesefeldt, J. Field, F. Filthaut, G. Finocchiaro, P.H. Fisher, G. Forconi, T. Foreman, K. Freudenreich, W. Friebel, M. Fukushima, M. Gailloud, Yu. Galaktionov, E. Gallo, S.N. Ganguli, P. Garcia-Abia, S.S. Gau, S. Gentile, M. Glaubman, S. Goldfarb, Z.F. Gong, E. Gonzalez, A. Gordeev, P. Göttlicher, D. Goujon, G. Gratta, C. Grinnell, M. Gruenewald, M. Guanziroli, A. Gurtu, H.R. Gustafson, L.J. Gutay, H. Haan, S. Hancke, K. Hangarter, M. Harris, A. Hasan, D. Hauschildt, C.F. He, T. Hebbeker, M. Hebert, G. Herten, U. Herten, A. Hervé, K. Hilgers, H. Hofer, H. Hoorani, L.S. Hsu, G. Hu, G.Q. Hu, B. Ille, M.M. Ilyas, V. Innocente, E. Isiksal, E. Jagel, B.N. Jin, L.W. Jones, R.A. Khan, Yu. Kamyshkov, Y. Karyotakis, M. Kaur, S. Khokhar, V. Khoze, M.-N. Kienzle, W. Kinnison, D. Kirkby, W. Kittel, A. Klimentov, A.C. König, O. Kornadt, V. Koutsenko, R.W. Kraemer, T. Kramer, V.R. Krastev, W. Krenz, J. Krizmanic, A. Kuhn, K.S. Kumar, V. Kumar, A. Kunin, A. van Laak, V. Lalieu, G. Landi, K. Lanius, D. Lanske, S. Lanzano, P. Lebrun, P. Lecomte, P. Lecoq, P. Le Coultre, D. Lee, I. Leedom, J.M. Le Goff, L. Leistam, R. Leiste, M. Lenti, J. Lettry, P.M. Levchenko, X. Leytens, C. Li, H.T. Li, J.F. Li, L. Li, P.J. Li, Q. Li, X.G. Li, J.Y. Liao, Z.Y. Lin, F.L. Linde, D. Linnhofer, R. Liu, Y. Liu, W. Lohmann, S. Lökös, E. Longo, Y.S. Lu, J.M. Lubbers, K. Lübelsmeyer, C. Luci, D. Luckey, L. Ludovici, X. Lue, L. Luminari, W.G. Ma, M. MacDermott, R. Magahiz, M. Maire, P.K. Malhotra, R. Malik, A. Malinin, C. Maña, D.N. Mao, Y.F. Mao, M. Maolinbay, P. Marchesini, A. Marchionni, J.P. Martin, L. Martinez, F. Marzano, G.G.G. Massaro, T. Matsuda, K. Mazumdar, P. McBride, T. McMahon, D. McNally, Th. Meinholz, M. Merk, L. Merola, M. Meschini, W.J. Metzger, Y. Mi, M. Micke, U. Micke, G.B. Mills, Y. Mir, G. Mirabelli, J. Mnich, M. Möller, B. Monteleoni, G. Morand, R. Morand, S. Morganti, V. Morgunov, R. Mount, E. Nagy, M. Napolitano, H. Newman, M.A. Niaz, L. Niessen, D. Pandoulas, F. Plasil, G. Passaleva, G. Paternoster, S. Patricelli, Y.J. Pei, D. Perret-Gallix, J. Perrier, A. Pevsner, M. Pieri, P.A. Piroué, V. Plyaskin, M. Pohl, V. Pojidaev, N. Produit, J.M. Qian, K.N. Qureshi, R. Raghavan, G. Rahal-Callot, P. Razis, K. Read, D. Ren, Z. Ren, S. Reucroft, O. Rind, C. Rippich, H.A. Rizvi, B.P. Roe, M. Röhner, S. Röhner, U. Roeser, Th. Rombach, L. Romero, J. Rose, S. Rosier-Lees, R. Rosmalen, Ph. Rosselet, J.A. Rubio, W. Ruckstuhl, H. Rykaczewski, M. Sachwitz, J. Salicio, J.M. Salicio, G. Sanders, G. Sartorelli, G. Sauvage, A. Savin, V. Schegelsky, D. Schmitz, P. Schmitz, M. Schneegans, M. Schöntag, H. Schopper, D.J. Schotanus, H.J. Schreiber, R. Schulte, S. Schulte, K. Schultze, J. Schütte, J. Schwenke, G. Schwering, C. Sciacca, I. Scott, R. Sehgal, P.G. Seiler, J.C. Sens, I. Sheer, V. Shevchenko, S. Shevchenko, X.R. Shi, K. Shmakov, V. Shoutko, E. Shumilov, N. Smirnov, A. Sopczak, C. Spartiotis, T. Spickermann, B. Spiess, P. Spillantini, R. Starosta, M. Steuer, D.P. Stickland, W. Stoeffl, B. Stöhr, H. Stone, K. Strauch, B.C. Stringfellow, K. Sudhakar, G. Sultanov, R.L. Sumner, L.Z. Sun, H. Suter, R.B. Sutton, J.D. Swain, A.A. Syed, A.A. Tang, E. Tarkovsky, L. Taylor, E. Thomas, C. Timmermans, Samuel C.C. Ting, S.M. Ting, Y.P. Tong, F. Tonisch, M. Tonutti, S.C. Tonwar, J. Tòth, G. Trowitzsch, K.L. Tung, J. Ulbricht, L. Urbàn, U. Uwer, E. Valente, R.T. Van de Walle, H. van der Graaf, I. Vetlitsky, G. Viertel, P. Vikas, U. Vikas, M. Vivargent, H. Vogel, H. Vogt, M. Vollmar, G. Von Dardel, I. Vorobiev, A.A. Vorobyov, An.A. Vorobyov, L. Vuilleumier, M. Wadhwa, W. Wallraff, C.R. Wang, G.H. Wang, J.H. Wang, Q.F. Wang, X.L. Wang, Y.F. Wang, Z. Wang, Z.M. Wang, J. Weber, R. Weill, T.J. Wenaus, J. Wenninger, M. White, R. Wilhelm, C. Willmott, F. Wittgenstein, D. Wright, R.J. Wu, S.L. Wu, S.X. Wu, Y.G. Wu, B. Wysłouch, Y.D. Xu, Z.Z. Xu, Z.L. Xue, D.S. Yan, B.Z. Yang, C.G. Yang, G. Yang, K.S. Yang, Q.Y. Yang, Z.Q. Yang, C.H. Ye, J.B. Ye, Q. Ye, S.C. Yeh, Z.W. Yin, J.M. You, M. Yzerman, C. Zaccardelli, L. Zehnder, M. Zeng, Y. Zeng, D. Zhang, D.H. Zhang, Z.P. Zhang, J.F. Zhou, R.Y. Zhu, H.L. Zhuang, and A. Zichichi

Subjects
Physics, Nuclear physics, Nuclear and High Energy Physics, Particle physics, 010308 nuclear & particles physics, Electron–positron annihilation, 0103 physical sciences, Hadron, 010306 general physics, 01 natural sciences, Spectral line, Mixing (physics)
Abstract

We have observed B0-B0 mixing in Z0→bb decays using hadronic events containing dileptons. The data sample corresponds to 118 200 hadron events at √s≈Mz. From a fit to the dilepton p and p⊥ spectra, we determine the mixing parameter to be χB=0.178-0.040 +0.049. © 1990.

Published
1990

97. A measurement of the forward-backward asymmetry

Author

Qi An, S. Lökös, K.S. Yang, Th. Rombach, Simonetta Gentile, Kenneth Francis Read, G. Conforto, C. Dionisi, L. Li, Dimitri Bourilkov, V. Plyaskin, D. Duchesneau, Pablo Garcia-Abia, Alain Hervé, B. Spiess, Y. Mi, A. Bay, Carlo Civinini, Alexander Malinin, M. Guanziroli, M. Maolinbay, R. Leiste, J. P. Martin, L. J. Gutay, H. Anderhub, J.F. Li, Luciano Romero, Bolek Wyslouch, Qian Wang, M. Fabre, S. X. Wu, X.G. Li, D. DiBitonto, Ph. Rosselet, M. Steuer, P. Marchesini, Ming Zeng, D. Pandoulas, T. McMahon, Raffaello D'Alessandro, S. C. Tonwar, T. Spickermann, S. L. Wu, Frank Filthaut, E. Shumilov, U. Becker, G. Sauvage, H. Suter, Georgi Sultanov, Y.F. Wang, M. Aguilar-Benitez, I. Duran, G. Forconi, Herwig Schopper, J. Weber, V. Lalieu, C. Grinnell, M. Möller, R. A. Khan, U. Roeser, M. Röhner, M. Schöntag, R. Rosmalen, Valentin V. Khoze, L.S. Hsu, W. Böhlen, V. Shoutko, M. White, Leonardo Merola, L. Urbàn, Bernard Ille, M. N. Kienzle, Harvey B Newman, K. Hilgers, C. F. He, V. Koutsenko, C-Q. Li, Petr Levchenko, S. Röhner, Y. H. Chang, F. Wittgenstein, George Alverson, Yanwen Liu, Qiang Li, R. Bizzarri, S. Hancke, L. Ludovici, V. P. Andreev, H. F. Chen, T. Azemoon, E. Drago, M. Sachwitz, Y.F. Mao, R. T. Van de Walle, G.J. Bobbink, Yu. Kamyshkov, T. Kramer, Ian Brock, F. DeNotaristefani, A. Arefiev, L. Niessen, L. Leistam, Vineet Kumar, T. Driever, J.P. Burq, R. de Asmundis, B. Bouwens, F. J. Eppling, L. W. Jones, M. Chemarin, J. J. Blaising, D. S. Yan, Jozsef Toth, Gaihe Yang, J. Lettry, Claudio Luci, D.N. Mao, K. N. Qureshi, Marcos Cerrada, D. Hauschildt, V. Shevchenko, U. Herten, Egidio Longo, Aa Vorobyov, I. Scott, M. Tonutti, G. Herten, C. Spartiotis, Mw Gruenewald, B. Monteleoni, R. Magahiz, E. Jagel, A. Pevsner, M. Harris, Kajari Mazumdar, S. Khokhar, G. M. Chen, Barry Blumenfeld, S. M. Ting, R.J. Wu, A. Sopczak, W. Friebel, G. Faber, G. B. Mills, P. Berges, Elisabetta Gallo, O. Fackler, M. Gailloud, P.G. Seiler, Igor Vorobiev, C. Camps, J. D. Swain, P. McBride, K. Freudenreich, Yu. Galaktionov, M.L. Chen, A. Kuhn, R. Morand, H. Haan, C. G. Yang, Chenliang Wang, M. Maire, F. Diez-Hedo, L. Antonov, W. Kittel, Valery Schegelsky, Antonino Zichichi, J.M. Lubbers, Xd Cai, Ph Fisher, J. Alcaraz, E. Dénes, R. Sehgal, Peter Denes, G. Schwering, Z. L. Xue, Mariagrazia Alviggi, H. Rykaczewski, R. Dolin, M. Hebert, Panos A Razis, J.C. Sens, R. Raghavan, A. C. König, Y.P. Tong, M. J. Glaubman, J. A. Bakken, Marcella Diemoz, E. Nagy, Paolo Bagnaia, Y. Karyotakis, C. Maña, L. Z. Sun, Marco Meschini, M. M. Ilyas, W. Ruckstuhl, D. P. Stickland, S. Reucroft, Laurent Vuilleumier, J. Krizmanic, P. Blömeke, K. S. Kumar, E. Isiksal, H. Fenker, A. Marchionni, Cheng Chen, M. Fukushima, D. Kirkby, H. El Mamouni, Howard A. Stone, I. Vetlitsky, G. Von Dardel, T. Fergusson, T.S. Dai, A. Gordeev, M. Micke, M. Schneegans, D. M. Lee, X. L. Wang, B. Stöhr, R. Fabbretti, V.R. Krastev, C. Zaccardelli, M. Vivargent, A. Degré, B. P. Roe, A. Böhm, G. Landi, Christine Buisson, R. L. Summer, L. Baksay, W. W. Kinnison, Z. M. Wang, S. Beingessner, Jean Fay, E. Gonzalez, T. Böhringer, M. Dhina, Y. Mir, F. Tonisch, Q. Fan, G. Coignet, C. H. Ye, Sc Yeh, F. Marzano, D. Boutigny, R.C. Ball, J.M. Qian, E. Valente, Adrian Biland, R. Weill, F. Ferroni, G. H. Wang, Y. Zeng, Ren-Yuan Zhu, W. Krenz, A. Klimentov, G. Fernandez, J. M. Le Goff, J. M. Salicio, J. Mnich, G. Gratta, T. Foreman, Z. Y. Lin, U. Micke, Z.Q. Yang, P. Arce, P. Vikas, Luciano Barone, J. Wenninger, S. Lanzano, Bernardo Adeva, D. Linnhofer, G. S. Sanders, Z.F. Gong, Y.J. Pei, R. Mount, D. McNally, D. Goujon, C.Y. Chien, Lamberto Luminari, Wolfgang Lohmann, H. Vogt, K.D. Shmakov, S. J. Fan, J. A. Rubio, F. Plasil, A. Bujak, Oliver Kornadt, E. Thomas, J.H. Wang, F.C. Erné, Q.Y. Yang, G. Chiefari, V. Pojidaev, M. Pohl, B. Bertucci, P. Duinker, D. Zhang, Mingshui Chen, F. Cesaroni, W. Wallraff, A. Gurtu, Vincenzo Innocente, G. Viertel, Guofan Hu, Samuel C.C. Ting, S. Shevchenko, V. Commichau, H. J. Schreiber, J. Ulbricht, Zhongyukun Xu, P. K. Malhotra, J. Y. Liao, O. Rind, J. Fehlmann, J. Berdugo, Nicanor Colino, J. Bao, Nikita Smirnov, M. Lenti, Federico Carminati, Zm Wang, B. Borgia, H. A. Rizvi, A. Kunin, H. O. Cohn, V. Morgunov, H. R. Gustafson, M. Bocciolini, M. Bourquin, A. L. Anderson, Hans J. Vogel, S. Morganti, K. Sudhakar, H. van der Graaf, J. Schütte, Pierre Lecomte, J. G. Branson, A. Engler, A. Hasan, D. Ren, K. Strauch, X. Leytens, Steven Goldfarb, J. Schwenke, G. Sartorelli, A. van Laak, X. Y. Cui, An.A. Vorobyov, M. Capell, Ying Wu, J. F. Zhou, Hafeez R. Hoorani, R.B. Sutton, G. Passaleva, Y. D. Xu, Z. W. Yin, S. N. Ganguli, Charles Timmermans, U. Vikas, T. Matsuda, D. Perret-Gallix, H. S. Fesefeldt, D.H. Zhang, M. MacDermott, J. Behrens, P. J. Li, F. Bruyant, A. Contin, Alexander Savin, B. N. Jin, S. Patricelli, M. A. Niaz, P. Lebrun, Fridolin Dittus, O. Adriani, Lucas Taylor, Q. Ye, X.R. Shi, M. Yzerman, R. Malik, Zhen Zhang, P. Extermann, I. Clare, J. Busenitz, A.M. Cartacci, I. Leedom, B. Z. Yang, B. L. Betev, W. J. Metzger, H. Hofer, K. L. Tung, U. Uwer, H.R. Dimitrov, G. Mirabelli, A. Chen, S. Rosier-Lees, P. Le Coultre, P. Göttlicher, J. Salicio, G.G.G. Massaro, J. D. Burger, F. Carbonara, Wolfgang Stoeffl, G. Morand, G. Rahal-Callot, K. Lübelsmeyer, Piero Spillantini, X. Lue, U. K. Chaturvedi, L. Martinez, Y. S. Lu, M.C. Chen, K. Hangarter, Jérôme Rose, K. Schultze, F. L. Linde, R. Wilhelm, J. H. Field, E. Tarkovsky, G. Trowitzsch, R. Starosta, D. Lanske, Zhuoxiang Ren, M. Wadhwa, D. J. Schotanus, D. Luckey, Gy L. Bencze, Reinhard W. Schulte, L. Zehnder, J. M. You, J.B. Ye, N. Produit, S. Banerjee, Tariq Aziz, A. A. Syed, B.C. Stringfellow, F. Crijns, G. Finocchiaro, Marcel Merk, Crisostomo Sciacca, J. Perrier, François Chollet, Marco Pieri, C. Rippich, M. Vollmar, Wen-Gan Ma, Konrad Deiters, D. Wright, Alberto Aloisio, Th. Meinholz, X. W. Tang, I. Sheer, P. A. Piroué, T. Angelov, K. Lanius, G. Hu, Carlos Willmott, Speranza Falciano, H. T. Li, R. Liu, S. S. Gau, P.V.K.S. Baba, H. L. Zhuang, G. Paternoster, D.W. Schmitz, Robert Clare, Thomas Hebbeker, Paul Lecoq, R. W. Kraemer, M. Napolitano, H. S. Chen, T.J. Wenaus, Manjit Kaur, H. Akbari, and D. Antreasyan

Subjects
Physics, Nuclear and High Energy Physics, Particle physics, Muon, Electron–positron annihilation, media_common.quotation_subject, Hadron, Weinberg angle, Electron, Asymmetry, Spectral line, Nuclear physics, Mixing (physics), media_common
Abstract

We have measured the forward-backward asymmetry in Z 0 → b b decays using hadronic events containing muons and electrons. The data sample corresponds to 118 200 hadronic events at √s≈Mz. From a fit to the single and dilepton p and P⊥ spectra, we determine A b b =0.130 −0.042 +0.044 including the correction for B 0 − B 0 mixing.

Published
1990

98. Determination of αs from jet multiplicities measured on the Z0 resonance

Author

L. Li, R.J. Wu, A. Sopczak, D. Duchesneau, J.M. Qian, G. Landi, W. Lange, Philip Kaaret, W. Ruckstuhl, D. P. Stickland, Y. Mir, J.F. Li, D. Pandoulas, T. McMahon, C. H. Ye, P. Vikas, A. Gordeev, H. Suter, Y.F. Wang, H. Anderhub, M. Schneegans, T. Spickermann, S. Kwan, Bernard Ille, Sc Yeh, M. Guanziroli, G. Fernandez, R. de Asmundis, D. Antreasyan, K. Sudhakar, M. J. Glaubman, R. Dolin, E. Dénes, H. El Mamouni, R. Sehgal, C. Zabounidis, P. Arce, R. Magahiz, D. Goujon, J. D. Swain, T.J. Wenaus, Sw. Banerjee, A. Leike, Manjit Kaur, P. McBride, R. Malik, Valentin V. Khoze, Vincenzo Innocente, Bz Yang, Jj Blaising, X. Leytens, Dimitri Bourilkov, L. Antonov, T. Kramer, G. Herten, Valery Schegelsky, Antonino Zichichi, J.M. Lubbers, Y. H. Chang, Ph Fisher, An.A. Vorobyov, George Alverson, B. Borgia, T. Matsuda, J. P. Martin, M. Bourquin, H. Rykaczewski, H. Akbari, Hafeez R. Hoorani, G. Faber, K. Strauch, Y. Karyotakis, W.G. Ma, S. X. Wu, Vineet Kumar, J. Ulbricht, E. Nagy, M. Vivargent, Christine Buisson, C. Goy, J. Krizmanic, E. Shumilov, A. Marchionni, J. M. Salicio, U. Micke, A. L. Anderson, A. Böhm, O. Adriani, A. van Laak, D. Linnhofer, J. Zoll, Z. M. Wang, R. Mount, L.S. Hsu, M. Schöntag, W. Böhlen, V. Shoutko, S. Rosier-Lees, I. Vorobiev, V.R. Krastev, C. Dionisi, E. Gonzalez, Pablo Garcia-Abia, Alain Hervé, M. G. Alviggi, Ying Wu, M. Fukushima, H. Haan, A. Kuhn, Zhuoxiang Ren, L. Urbàn, D. DiBitonto, M. Wadhwa, J. F. Zhou, A. Klimentov, J. A. Bakken, Lamberto Luminari, D. J. Schotanus, A. Bay, H. Nowak, Jean Fay, M. Dhina, S. Lanzano, Bernardo Adeva, F. Ferroni, V. Koutsenko, Y. Zeng, Jozsef Toth, Carlo Civinini, M. Maolinbay, J. Berdugo, M. Tonutti, X.R. Shi, J. M. You, J. Lettry, Claudio Luci, P. Le Coultre, X.G. Li, N. Produit, M. Aguilar-Benitez, Yu. Kamyshkov, J. Fehlmann, M. Steuer, G. Forconi, B. Spiess, I. Duran, I. Clare, J. Busenitz, Herwig Schopper, Elisabetta Gallo, K. Hangarter, I. Vetlitsky, M. White, D.N. Mao, Petr Levchenko, J.M. Thenard, A.M. Cartacci, B. Monteleoni, Egidio Longo, H.R. Dimitrov, Mw Gruenewald, R. Starosta, C. Souyri, S. Röhner, Chenliang Wang, F. Wittgenstein, J. Weber, P. Göttlicher, C-Q. Li, G. A. Yang, G. Sauvage, Pierre Lecomte, G. Sartorelli, M. Möller, L. Ludovici, P. Schmitz, W. Kittel, D. Luckey, Gy L. Bencze, M. Hebert, Panos A Razis, E. Drago, L. Niessen, Reinhard W. Schulte, R.C. Ball, J. D. Burger, H. Vogt, S. Reucroft, Sau Lan Wu, Z.Y. Lin, G. Paternoster, T. Driever, D.W. Schmitz, C. G. Yang, J. M. Le Goff, Charles Timmermans, D. Boutigny, V. Plyaskin, C. Camps, D. Perret-Gallix, R. Bizzarri, S. Hancke, Ian Brock, Adrian Biland, G. Rahal-Callot, K. Freudenreich, H. Fenker, P. Blömeke, M. Harris, J.G. Branson, S. Shevchenko, M. Fabre, Z.F. Gong, A. Malinin, V. Lalieu, F. DeNotaristefani, K. N. Qureshi, H.F. Chen, M. M. Ilyas, K. S. Kumar, Luciano Romero, Qian Wang, Harvey B Newman, K. Hilgers, G.B. Mills, K.D. Shmakov, S. J. Fan, B. L. Betev, M. Micke, Georgi Sultanov, J. A. Rubio, L. Leistam, R. A. Khan, Robert Clare, R. Fabbretti, Ph. Rosselet, S. Nowak, M. Sachwitz, C. F. He, Samuel C.C. Ting, D. Kaplan, K. Schultze, A. Heavey, E. Tarkovsky, Qiang Li, Steven Goldfarb, T. Riemann, Z.Q. Yang, P.G. Seiler, F. Diez-Hedo, V. P. Andreev, G.J. Bobbink, S. Beingessner, Peter Denes, A. Pevsner, G. Morand, A. Engler, D. Lanske, M. Chemarin, R.B. Sutton, D.H. Zhang, M. Capell, W. Lohmann, G. M. Chen, C. Spartiotis, M. MacDermott, Thomas Hebbeker, Paul Lecoq, R. W. Kraemer, M. Gailloud, Paolo Bagnaia, M. Napolitano, Barry Blumenfeld, J. Mnich, E. Jagel, Mingshui Chen, I. Sheer, Helmut Vogel, U. Herten, H. S. Fesefeldt, P. Berges, G. Mirabelli, E. Thomas, Speranza Falciano, J.H. Wang, P. K. Malhotra, H. A. Rizvi, R. Morand, Z. L. Xue, M. A. Niaz, R. Rosmalen, W. Wallraff, X. L. Wang, Guofan Hu, K. Lübelsmeyer, Piero Spillantini, Y. Mi, M. Maire, H. van der Graaf, P. Duinker, G. Chiefari, J.P. Burq, Howard A. Stone, T.S. Dai, Yanwen Liu, D. Ren, A. Arefiev, H. S. Chen, H.J. Schreiber, Q. Fan, D. Zhang, W. J. Metzger, P. Extermann, J. Bao, I. Leedom, H. Hofer, K. L. Tung, G.G.G. Massaro, Z. W. Yin, U. Vikas, A. Contin, Aa Vorobyov, A. Kunin, S. C. Tonwar, F. Carbonara, S. N. Ganguli, L. Martinez, J.C. Sens, A. Degré, F. L. Linde, R. Raghavan, Thomas Ferguson, A. C. König, Y.P. Tong, Laurent Vuilleumier, G. Schwering, Kajari Mazumdar, R. Leiste, E. Isiksal, L. Montanet, S. Khokhar, M. Vollmar, F. Marzano, G. Coignet, W. Krenz, G. H. Wang, Marco Meschini, A. A. Syed, J. Wenninger, V. Pojidaev, Nikita Smirnov, Xd Cai, Zm Wang, D. Kirkby, B. P. Roe, Qi An, D. Wright, B.C. Stringfellow, F. Crijns, F. Cesaroni, J. Y. Liao, S. Lökös, K.S. Yang, G. Finocchiaro, J. Schütte, A. Bujak, Oliver Kornadt, M. Pohl, T. Foreman, Y.J. Pei, Marcel Merk, Th. Rombach, J. Perrier, F. Bruyant, V. Morgunov, B. Bertucci, Nicanor Colino, F. Tonisch, Simonetta Gentile, Kenneth Francis Read, G. Conforto, A. Savin, T. Angelov, M.L. Chen, K. Lanius, M. Gettner, W. Friebel, G. Hu, C. Maña, Marcella Diemoz, X. Lue, U. K. Chaturvedi, G. Trowitzsch, Carlos Willmott, Y. S. Lu, G. Von Dardel, T. Böhringer, P. Marchesini, Jérôme Rose, R. Wilhelm, J. H. Field, Ming Zeng, H. T. Li, M. Röhner, Ren-Yuan Zhu, Luciano Barone, F.C. Erné, Q.Y. Yang, A. Gurtu, V. Commichau, R. Liu, M. Bocciolini, Y.F. Mao, R. T. Van de Walle, A. Hasan, J. Behrens, E. Valente, R. Weill, P. J. Li, D. McNally, G. Viertel, P. Lebrun, Fridolin Dittus, S. S. Gau, P.V.K.S. Baba, S. Morganti, J. Schwenke, X. Y. Cui, S.Y. Zhang, U. Uwer, A. Chen, J. Salicio, Z.Z. Xu, Yu. Galaktionov, J. Alcaraz, Tariq Aziz, Cheng Chen, B. Stöhr, C. Zaccardelli, Raffaello D'Alessandro, C. Grinnell, Leonardo Merola, W. Walk, T. Azemoon, Marcos Cerrada, Crisostomo Sciacca, Marco Pieri, C. Rippich, B. N. Jin, L. Zehnder, Zp Zhang, Konrad Deiters, Alberto Aloisio, A. Ricker, A. Grimes, W.D. Nowak, Th. Meinholz, X. W. Tang, P. A. Piroué, R. L. Summer, L. Baksay, V.G. Shevchenko, G. Gratta, Boleslaw Wyslouch, C.Y. Chien, L. J. Gutay, U. Becker, F. J. Eppling, L. W. Jones, D. S. Yan, S. M. Ting, Federico Carminati, S. Patricelli, Q. Ye, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), L3, and IHEF (IoP, FNWI)

Subjects
Physics, Nuclear and High Energy Physics, Particle physics, 010308 nuclear & particles physics, Emerging technologies, media_common.quotation_subject, Field (Bourdieu), Skill, Context (language use), Space (commercial competition), Investment (macroeconomics), 01 natural sciences, Celling act, Microeconomics, Networking, Local, Information, Phenomenon, 0103 physical sciences, Mediation, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], 010306 general physics, Empowerment, Particle Physics - Experiment, media_common
Abstract

Whatever the field, major change implies as much as deep transformation of thinking i.e to put in network new skills in particular, those made available by the availability of new technologies. In this context, only one individual cannot join together all necessary skills. It becomes clear that the goal of space valorization cannot be considered without relational investment between the partners and their accumulated background. The local empowerment concerns a collective phenomenon of acquisition and development of skills rests on an learning way appropriate to the potential of the territory to form or promote. The local mediation sets for objective the creation of relations between pre-existent skills and their transfer between the actors, individuals or groups, private or public. But the capacity of the territory to solve these problems will depend closely on the richness of the network and co-operations which it shelters or it will suggest.

Published
1990

99. The construction of the L3 experiment

Author

B. Adeva, M. Aguilar-Benitez, H. Akbari, J. Alcaraz, A. Aloisio, J. Alvarez-Taviel, G. Alverson, M.G. Alviggi, H. Anderhub, A.L. Anderson, A.M. Angelov, T.H. Angelov, G.H. Antchev, L. Antonov, D. Antreasyan, A. Arefiev, I.H. Atanasov, B. Auroy, R. Ayad, O.L. Ayranov, T. Azemoon, T. Aziz, U. Bachmann, P. Bähler, J.A. Bakken, L. Baksay, H. Baldinger, R.C. Ball, J. Ballansat, S. Banerjee, J. Bao, G. Barbier, L. Barone, G. Basti, A. Bay, F. Beauvais, U. Becker, R. Beissel, S. Bendig, P. Béné, J. Berdugo, P. Berges, M. Berthet, Y. Bertsch, B.L. Betev, A. Biland, A. Bischoff, M. Bischops, R. Bizzarri, J.J. Blaising, M. Blanc, P. Blömeke, B. Blumenfeld, G.J. Bobbink, M. Bocciolini, K.D. Boffin, W. Bohlen, A. Böhm, T. Böhringer, H. Bonnefon, C. Bopp, B. Borgia, K. Bosseler, J.F. Bottolier, M. Bourquin, D. Boutigny, P. Bowditch, J.G. Branson, D. Braun, I.C. Brock, F. Bruyant, M. Buchholz, B. Bücken, W. Bulgeroni, R. Burel, J.D. Burger, C. Burgos, J.P. Burq, L. Caiazzo, M. Caillat, B. Camberlin, D. Campana, C. Camps, V. Canale, M. Capell, F. Carbonara, F. Carminati, A.M. Cartacci, M. Cerrada, F. Cesaroni, Y.H. Chang, J.W. Chapman, M. Chemarin, A. Chen, C. Chen, H.F. Chen, H.S. Chen, M. Chen, M.L. Chen, S.R. Chendvankar, G. Chevenier, S. Chidzik, G. Chiefari, C.Y. Chien, F. Chollet, M. Chumakov, C. Civinini, I. Clare, R. Clare, G. Coignet, N. Colino, V. Commichau, G. Conforto, P. Cristofori, F. Crijns, X.Y. Cui, T.S. Dai, R. D'Alessandro, M. Daniel, X. De Bouard, B. Debye, G. Decreuse, A. Degré, K. Deiters, E. Dénes, P. Denes, F. DeNotaristefani, M. Deutschmann, M. Dhina, B. Didierjean, M. Diemoz, M. Dietrich, H.A. Dimitrov, C. Dionisi, F. Dittus, M. Dohmen, R. Dolin, J.F. Donahue, A. Donat, E. Drago, K.H. Dreger, T. Driever, G. Dromby, P. Duinker, I. Duran, M. Elkacimi, H. Elmamouni, A. Engler, F.J. Eppling, F.C. Erné, I. Erne, H. Esser, P. Extermann, R. Fabbretti, G. Faber, S. Falciano, T. Falk, S.J. Fan, M. Favre, J. Fay, S. Fehér, J. Fehlmann, M. Feldmann, H. Fenker, T. Ferguson, M. Fernandez, F. Ferroni, H. Fesefeldt, J. Field, J.M. Figarola, C.F. Figueroa, G.A. Filipov, B. Foligné, G. Forconi, T. Foreman, V. Franzke, W. Frei, K. Freudenreich, W. Friebel, M. Fukushima, G. Gaillard, M. Gailloud, Yu. Galaktionov, E. Gallo, S.N. Ganguli, D. Garelick, S.S. Gau, G. Gavrilov, E. Gennari, S. Gentile, M. Gettner, C. Girard, M. Glaubman, S. Goldfarb, Z.F. Gong, E. Gonzalez, A. Gordeev, Yu. Gorodkov, P. Göttlicher, C. Goy, M. Goyot, G. Gratta, A. Grimes, C. Grinnell, M. Gruenewald, M. Guanziroli, S. Guerra, C. Guillon, A. Gurtu, D. Güsewell, H.R. Gustafson, M. Haensli, M. Haan, C. Haller, T. Hamacher, H. Hammers, K. Hangarter, S. Hancke, M. Harris, D. Harting, F.G. Hartjes, C.F. He, A. Heavey, T. Hebbeker, M. Hebert, R. Heller, Ch. Helmrath, J. Herrmann, G. Herten, U. Herten, A. Hervé, H. Hesser, G. Hilgers, K. Hilgers, H. Hofer, M. Hofer, T. Hofer, F. Hoffmann, U. Horisberger, I. Horvath, L.S. Hsu, G.Q. Hu, B. Ille, M.M. Ilyas, G. Improta, V. Innocente, E. Isiksal, E. Jagel, B.N. Jin, L.W. Jones, M. Jongmanns, H. Jung, P. Kaaret, O. Kaelin, W. Kaestli, Yu. Kamyshkov, D. Kaplan, W. Karpinski, Y. Karyotakis, W. Kertzer, V. Khoze, G. Kirchhoff, W. Kittel, A. Klimentov, P.F. Klok, M. Kollek, M. Koller, A.C. König, O. Kornadt, V. Koutsenko, R.W. Kraemer, V.R. Krastev, A. Kratel, W. Krenz, A. Kuhn, A. Kunin, S. Kwan, J. Lacotte, M. LaMarra, G. Landi, W. Lange, K. Lanius, D. Lanske, S. Lanzano, J.M. Le Goff, J.C. Le Marec, D. Lea, M. Lebeau, P. Lebrun, P. Lecomte, J. Lecoq, P. Le Coultre, I. Leedom, A. Léger, F. Lehmann, L. Leistam, R. Leiste, E. Lejeune, B. Leoni, J. Lettry, X. Leytens, C. Li, H.T. Li, L. Li, P.J. Li, X.G. Li, J.Y. Liao, Z.Y. Lin, F.L. Linde, D. Linnhöfer, E. Loftin, W. Lohmann, S. Lökös, E. Longo, Y.S. Lu, J.M. Lubbers, K. Lübelsmeyer, C. Luci, D. Luckey, X. Lue, L. Luminari, G. Lunadei, F. Lürken, H. Ma, W.G. Ma, M. MacDermott, N. Madjar, R. Magahiz, M. Maire, P.K. Malhotra, A. Malinin, C. Mana, F. Manna, G. Manto, Y.F. Mao, M. Maolinbay, P. Marchesini, A. Marchionni, M. Markwalder, P. Marsden, J.P. Martin, L. Martinez, H.U. Martyn, F. Marzano, V. Marzullo, F. Masciocchi, G.G.G. Massaro, L. Massonnet, T. Matsuda, G. Maurelli, K. Mazumdar, P. McBride, G. Medici, H. Meier, Th. Meinholz, M. Merk, R. Mermod, L. Merola, M. Meschini, W.J. Metzger, M. Micke, U. Micke, G.B. Mills, J. Mnich, M. Moeller, A. Molinero, L. Montanet, B. Monteleoni, R. Montino, G. Morand, R. Morand, S. Morganti, V. Morgunov, R. Mount, M. Moynot, P. Mugnier, W. Nägeli, E. Nagy, M. Napolitano, S. Neboux, H. Newman, Ch. Neyer, K. Nguyen, L. Niessen, A. Nikitin, W.D. Nowak, M. Okle, P. Olmos, J. Onvlee, D. Osborne, J. Ossmann, D. Pandoulas, H. Paprotny, A. Parmentola, G. Passeggio, G. Paternoster, S. Patricelli, Y.J. Pei, Y. Peng, D. Perret-Gallix, J. Perrier, E. Perrin, G. Perrot, P. Petitpas, P. Petschner, A. Pevsner, J. Pier-Amory, M. Pieri, G. Pierschel, P.A. Piroué, V. Plyaskin, M. Pohl, V. Pojidaev, C.L.A. Pols, T. Ponomareff, J. Potyka, N. Produit, P. Prokofiev, F. Pruja, G. Pütz, J.M. Qian, R. Raghavan, P. Razis, K. Read, P. Reddick, K. Reissmann, D. Ren, S. Reucroft, D. Rey, M. Reynaud, X. Ricadonna, J-P. Richeux, C. Rippich, U. Rinsche, R. Rocco, S. Rodriguez, B.P. Roe, M. Röhner, S. Röhner, Th. Rombach, L. Romero, J. Rose, U. Röser, S. Rosier-Lees, J.A. Rubio, W. Ruckstuhl, H. Rykaczewski, P. Sahuc, J. Salicio, S. Saran, G. Sauvage, A. Savin, T. Schaad, B. Schafheitle, V. Schegelsky, A. Schetkovsky, F. Schild, R. Schillsott, P. Schmitt, D. Schmitz, P. Schmitz, M. Schneegans, M. Schneider, E. Schneevogt, M. Schöntag, D.J. Schotanus, H. Schuijlenburg, R. Schulte, A.Schultz Von Dratzig, K. Schultze, J. Schwenke, G. Schwering, C. Sciacca, P.G. Seiler, J.C. Sens, I. Sheer, V. Shevchenko, S. Shevchenko, X.R. Shi, K. Shmakov, V. Shoutko, E. Shumilov, R. Siedling, N. Smirnov, V. Souvorov, C. Souyri, I. Spangler, T. Spickermann, B. Spiess, P. Spillantini, R. Starosta, M. Steuer, D.P. Stickland, B. Stöhr, H. Stone, K. Strauch, K. Sudhakar, R.L. Sumner, H. Suter, R.B. Sutton, H. Szczesny, J. Tang, X.W. Tang, E. Tarkovsky, A. Tavenrath, V. Tchudakov, J.M. Thenard, E. Thomas, T. Thon, H. Thuerig, M. Thulen, C. Timmermans, Samuel C.C. Ting, S.M. Ting, F. Tonisch, Y.P. Tong, M. Tonutti, S.C. Tonwar, J. Tòth, W. Toth, G. Trowitzsch, K.L. Tung, J. Ulbricht, L. Urbàn, E. Valente, R.T. van de Walle, H. van der Graaf, V. Vanzanella, M. Vergain, I. Vetlitsky, H. Vey, G. Viertel, M. Vivargent, H. Vogel, S. Volkov, M. Vollmar, H.P. von Gunten, I. Vorobiev, A. Vorobyov, L. Vuilleumier, S. Waldmeier, W. Walk, W. Wallraff, C.Y. Wang, G.H. Wang, J.H. Wang, Q.F. Wang, X.L. Wang, Y.F. Wang, Z.M. Wang, D. Wassenberg, D. Wegmann, R. Weill, T.J. Wenaus, P. Wenger, J. Wenninger, M. White, R. Wilhelm, C. Willmott, H.P. Wirth, F. Wittgenstein, R.J. Wu, S.X. Wu, Y.G. Wu, B. Wyslouch, F.Y. Xi, Z.Z. Xu, Z.L. Xue, D.S. Yan, K.D. Yanev, B.Z. Yang, C.G. Yang, K.S. Yang, Q.Y. Yang, Z.Q. Yang, C.H. Ye, S.C. Yeh, Z.W. Yin, C. Zabounidis, L. Zehnder, Y. Zeng, D.H. Zhang, S.Y. Zhang, Z.P. Zhang, B. Zhou, J.F. Zhou, Z.P. Zhou, R.Y. Zhu, A. Zichichi, M. Zofka, J. Zoll, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), L3, B., Adeva, Aloisio, Alberto, Alviggi, Mariagrazia, Canale, Vincenzo, Chiefari, Giovanni, Merola, Leonardo, Napolitano, Marco, Paternoster, Giovanni, Patricelli, Sergio, and Sciacca, Crisostomo

Subjects
Physics, Nuclear and High Energy Physics, Wire chamber, Particle physics, Muon, Photon, Physics::Instrumentation and Detectors, 010308 nuclear & particles physics, Detector, Electron, 01 natural sciences, Particle detector, Nuclear physics, 0103 physical sciences, Large Electron–Positron Collider, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], Measuring instrument, High Energy Physics::Experiment, 010306 general physics, Instrumentation
Abstract

The L3 experiment is one of the six large detectors designed for the new generation of electron-positron accelerators. It is the only detector that concentrates its efforts on limited goals of measuring electrons, muons and photons. By not attempting to identify hadrons, L3 has been able to provide an order of magnitude better resolution for electrons, muons and photons. Vertices and hadron jets are also studied. The construction of L3 has involved much state of the art technology in new principles of vertex detection and in new crystals for large scale electromagnetic shower detection and ultraprecise muon detection. This paper presents a summary of the construction of L3.

Published
1990

100. A search for heavy charged and neutral leptons from Z0 decays

Author

Dimitri Bourilkov, R.J. Wu, M. MacDermott, Raffaello D'Alessandro, M.L. Chen, P.J. Li, C. Grinnell, M. A. Niaz, Leonardo Merola, A. Gordeev, C.H. Ye, R. Starosta, V. Commichau, G.Q. Hu, D. Pandoulas, T. Azemoon, P. Extermann, B. Ille, Marcella Diemoz, C. Buisson, A. Böhm, I. Leedom, H. Hofer, K. L. Tung, M. Möller, B. P. Roe, G. Von Dardel, A. Degré, T. Böhringer, G. Morand, J. Behrens, H. Anderhub, C.R. Wang, Q.Y. Yang, Z.W. Yin, U. Uwer, Fridolin Dittus, Z.Y. Lin, O. Kornadt, M. Fukushima, J.C. Sens, R. Raghavan, Harvey B Newman, J. Lettry, Claudio Luci, Elisabetta Gallo, C.F. He, Egidio Longo, S. Shevchenko, A. C. König, Laurent Vuilleumier, E. Isiksal, J.P. Martin, A. Chen, F. Ferroni, S. Beingessner, D. DiBitonto, A. Bujak, R. L. Sumner, F. Tonisch, G. H. Wang, W. Lohmann, W. Wallraff, D. Perret-Gallix, M. Guanziroli, J. Wenninger, J.P. Burq, Ph. Rosselet, M. Steuer, Zm Wang, G. Forconi, B. Stöhr, C. Zaccardelli, M. Pohl, M. M. Ilyas, R. Leiste, X.G. Li, Yu. Kamyshkov, D. Boutigny, P. K. Malhotra, H. A. Rizvi, H.J. Schreiber, L. J. Gutay, U. Roeser, R. Fabbretti, R. de Asmundis, J. Weber, L.S. Hsu, J. Salicio, Tariq Aziz, Marco Meschini, J. Fay, K. Schultze, Yu. Galaktionov, H. van der Graaf, M. Zeng, D.N. Mao, S. Reucroft, U. Becker, M. Schöntag, Mw Gruenewald, H. Haan, Ren-Yuan Zhu, Luciano Barone, R. Liu, R.C. Ball, Adrian Biland, V. Lalieu, D.S. Yan, H. Fenker, R. T. Van de Walle, G.B. Mills, K.S. Kumar, R. Weill, M. Gailloud, A.M. Cartacci, D. Kirkby, E. Thomas, H.T. Li, T. Spickermann, G. Herten, L. Urbàn, G. Landi, M. J. Glaubman, F.C. Erné, C. G. Yang, I. Scott, L. Li, G. Faber, H.F. Chen, J. Alcaraz, A. Gurtu, Aa Vorobyov, Y.J. Pei, M. Chemarin, J.Y. Liao, R.A. Khan, F. J. Eppling, L. W. Jones, A. Kunin, E. Valente, E. Jagel, Y. Zeng, P. Vikas, V. Shevchenko, T. Foreman, H.R. Dimitrov, M. Lenti, P. Arce, M. Bocciolini, K. Freudenreich, P.V.K.S. Baba, G. Sartorelli, H. L. Zhuang, D. Goujon, D. McNally, S. M. Ting, J.M. You, Mingshui Chen, A. L. Anderson, D. Duchesneau, M. Maire, E. Nagy, A. Hasan, M. Cerrada, Z. Ren, C. Chen, Vincenzo Innocente, N. Smirnov, F. Marzano, I. Vetlitsky, D. Lanske, B. Bertucci, W. J. Metzger, G. Viertel, J.M. Qian, C. Li, I. Vorobiev, Z.M. Wang, K. N. Qureshi, Y. D. Xu, P. Blömeke, P. Lebrun, X. Leytens, V. Shoutko, Crisostomo Sciacca, D. Zhang, Marco Pieri, A. Engler, Jd Burger, K. Sudhakar, C. Rippich, S. Morganti, G. Rahal-Callot, G.G.G. Massaro, Nicanor Colino, H. El Mamouni, J. G. Branson, M. Capell, J. A. Bakken, Samuel C.C. Ting, G. Fernandez, X. Lue, K.S. Yang, L. Romero, Federico Carminati, P. McBride, U. Micke, K. Lübelsmeyer, Z.Z. Xu, X. Y. Cui, J. Tòth, S. Röhner, Y. Mi, H. R. Gustafson, Y. S. Lu, S. N. Ganguli, J. Schwenke, Steven Goldfarb, F. Carbonara, M. Tonutti, J. M. Salicio, R.B. Sutton, G. Passaleva, D.H. Zhang, S. Lökös, M.C. Chen, U.K. Chaturvedi, Konrad Deiters, G. Sauvage, A. Malinin, Th. Rombach, R. Wilhelm, J. H. Field, W. Krenz, G. Schwering, An.A. Vorobyov, T. Matsuda, Alberto Aloisio, S. C. Tonwar, L. Martinez, L. Niessen, S. Patricelli, F. L. Linde, W. Böhlen, Simonetta Gentile, K. Hilgers, M. Schneegans, Jj Blaising, O. Adriani, Thomas Ferguson, T. Kramer, Kenneth Francis Read, R. Morand, Q. Ye, V. Schegelsky, G. Conforto, L. Z. Sun, V. Pojidaev, Th. Meinholz, Lucas Taylor, K. Hangarter, S.J. Fan, Sc Yeh, A. Klimentov, S.S. Gau, J.F. Li, T. Angelov, C. Maña, H. Vogt, X. W. Tang, K. Lanius, I. Sheer, G. Yang, Jian Wang, P. A. Piroué, J. Rose, C. Willmott, Mariagrazia Alviggi, D. Linnhofer, W. Friebel, M. Bourquin, L. Baksay, Speranza Falciano, G. Coignet, B. N. Jin, K. Strauch, P. Duinker, P.G. Seiler, F. Diez-Hedo, Peter Denes, V. Morgunov, Bolek Wyslouch, Qian Wang, X.L. Wang, J. Bao, Paolo Bagnaia, G. Gratta, R. Mount, V. Koutsenko, P. Schmitz, B. Borgia, L. Zehnder, J.B. Ye, C.Y. Chien, S. Banerjee, Zp Zhang, A. van Laak, W. Ruckstuhl, D. P. Stickland, H. Suter, Y.F. Wang, Y. Mir, S. Rosier-Lees, R. Malik, A. Pevsner, Barry Blumenfeld, Antonino Zichichi, J.M. Lubbers, U. Herten, Ph Fisher, H. Rykaczewski, Q. Z. Li, Y. Karyotakis, X.R. Shi, L. Antonov, I. Clare, J. Busenitz, S. Schulte, V. Kumar, J. Krizmanic, A. Marchionni, Q. An, M. Dhina, M. Micke, V. Plyaskin, T. Hebbeker, D. J. Schotanus, P. Levchenko, V.R. Krastev, E. Gonzalez, M. Röhner, N. Produit, J. Ulbricht, C. Spartiotis, S. Lanzano, Bernardo Adeva, A. A. Syed, Howard A. Stone, T.S. Dai, Q. Fan, B.C. Stringfellow, B. Spiess, V. Khoze, F. Crijns, R. Rosmalen, G. Finocchiaro, Marcel Merk, B.Z. Yang, J. Perrier, R. Bizzarri, Ian Brock, F. DeNotaristefani, L. Leistam, M. Kaur, G. Hu, B. Monteleoni, G. Chiefari, W. Kittel, P. Berges, R. Sehgal, W.G. Ma, M. Vivargent, C. Dionisi, Alain Hervé, A. Bay, A. Arefiev, Carlo Civinini, M. Maolinbay, M. Aguilar-Benitez, I. Duran, Herwig Schopper, M. White, F. Wittgenstein, L. Ludovici, E. Drago, Sau Lan Wu, T. Driever, R. Schulte, A. Kuhn, M. Harris, J.F. Zhou, S. Hancke, Y. H. Chang, George Alverson, Z.Q. Yang, G. Trowitzsch, Helmut Vogel, Kajari Mazumdar, S. Khokhar, E. Dénes, Xd Cai, F. Cesaroni, D. Ren, H. Fesefeldt, U. Vikas, A. Contin, J. Mnich, M. Hebert, Panos A Razis, J. Schütte, M. Sachwitz, F. Bruyant, R. Dolin, P. Garcia-Abia, J. M. Le Goff, K. Shmakov, Z.F. Gong, M. Wadhwa, J. A. Rubio, T. McMahon, E. Shumilov, R. Magahiz, J. D. Swain, A. Savin, D. Wright, C. Camps, P. Le Coultre, D. Schmitz, D. Antreasyan, G. Paternoster, G. Mirabelli, P. Marchesini, Robert Clare, D. Luckey, Gy L. Bencze, Y.G. Wu, Paul Lecoq, R. W. Kraemer, M. Napolitano, Piero Spillantini, H. S. Chen, S.X. Wu, Y.P. Tong, E. Tarkovsky, A. Sopczak, T.J. Wenaus, H. Akbari, Y.F. Mao, Lamberto Luminari, J. Berdugo, P. Göttlicher, J. Fehlmann, Z.L. Xue, Pierre Lecomte, M. Vollmar, Charles Timmermans, O. Rind, Hafeez R. Hoorani, M. Fabre, Georgi Sultanov, V. P. Andreev, G.J. Bobbink, B.L. Betev, G. M. Chen, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CMS, Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), L3, and IHEF (IoP, FNWI)

Subjects
Physics, Nuclear and High Energy Physics, Particle physics, Sterile neutrino, 010308 nuclear & particles physics, Astrophysics::High Energy Astrophysical Phenomena, Electron–positron annihilation, High Energy Physics::Phenomenology, Dirac (software), 01 natural sciences, Lower limit, Nuclear physics, MAJORANA, grey literature, Citation analysis, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], High Energy Physics::Experiment, Neutrino, Nuclear Experiment, 010306 general physics, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Particle Physics - Experiment, Lepton
Abstract

We have searched for charged and neutral leptons. We exclude stable Dirac neutrinos below 42.8 GeV and stable Majorana neutrinos below 34.8 GeV. From a search for unstable neutrinos we exclude masses below 46.4 GeV (Dirac) and below 45.1 GeV (Majorana). We exclude all masses of sequential charged and neutral leptons, except if both masses are larger than 42.8 GeV (for stable Dirac neutrinos). All mass limits correspond to 95% CL.

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results